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ABSTRACT
Campylobacter infections are the leading bacterial cause of diarrhea worldwide
with potentially profound impacts on pediatric patients in the developing world. It is still
unclear how Campylobacter impacts human hosts, though it is becoming increasingly
evident that Campylobacters infection’s impact is a multifactorial process that depends
on the host immune response, the gastrointestinal microbiota, various bacterial derived
metabolites, and possibly the nutritional status of the host. Since these factors likely
differ between human-host and bacteria in the developed and developing worlds, it is
important that studies comprehensively define these attributes in well characterized
clinical cohorts in both settings. In this study, we analyzed the microbiota, the
metabolome, and the micronutrient profile of fecal samples from Campylobacterinfected pediatric subjects in Colombia during a case-controlled study of acute diarrheal
disease. Here, we report that Campylobacter-infected children exhibited significant
changes to the gastrointestinal environment when compared to uninfected cohorts,
including shifts in Proteobacteria abundance and concentrations of gastrointestinal
metabolites, and decreases in almost all essential micronutrients. These observations
have led to several hypotheses on how Campylobacter infection may affect host
biology, and ultimately negatively impact clinical outcome in young children throughout
the developing world.
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CHAPTER ONE – LITERATURE REVIEW
Statement of Contribution
The research presented in this thesis is a represents a significant portion of a
collaborative study. The fecal samples and patient data were provided by Dr. Oscar
Gomez-Duarte of University at Buffalo (Buffalo, New York, USA) and AE Farfán-García
of Universidad de Santander (Bucaramanga, Colombia). The UHPLC-MS/MS analysis
of fecal metabolites and inductively-coupled plasma mass spectrometry (ICP-MS)
analysis of fecal micronutrients were both outsourced to other laboratories. All other
data collection, processing, and analysis were performed by the author.

Campylobacter
Campylobacter is a Gram-negative, spiral or ‘S’-shaped bacterium, and a
member of the epsilon group of the phylum Proteobacteria [1]. Campylobacter is a
motile organism propelled in a corkscrew fashion by either a single polar flagellum or
bipolar flagella [1]. While Campylobacters are the most common cause of bacterial
derived-gastroenteritis in the world [2], there is significantly less knowledge of the
pathogenic mechanisms of its primary human pathogens C. jejuni and C. coli compared
to other enteric pathogens such as Escherichia coli, Salmonella, and Vibrio species [2].
This is attributed to the overall microaerophilic nature of the Campylobacter genus,
which along with the inability to utilize mice as a pertinent animal model for human
disease, increases the difficulty of studying Campylobacter in a laboratory setting [3].
There are currently 17 species that make up the genus Campylobacter with C. jejuni
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and C. coli most commonly associated with human disease [1]. Campylobacter that
cause disease are found in food animals such as poultry, cattle, pigs, and sheep, as
well as in pets, including cats and dogs [1, 4]. The most common route of transmission
in developed countries is through the consumption of undercooked meats, especially
chicken [4, 5]. The sources of infection in low- and middle –income countries (LMIC)
are less understood, though it is thought to be primarily contaminated drinking water [6].
Onset of Campylobacter-induced disease usually occurs 2-5 days after ingestion,
and symptoms include diarrhea (frequently bloody), abdominal pain, fever, headache,
nausea, and/or vomiting [5]. The disease is considered self-limiting with symptoms
lasting 3-6 days. Campylobacter-infection is associated with post-infection
complications. One association is an intestinal disorder causing stomach pain, gas,
diarrhea, and constipation known as irritable bowel syndrome [1, 7]. Reactive arthritis, a
painful inflammation of the joints which can last for several months, is another
associated possible complication [1]. Campylobacter-infection is recognized as the
trigger for up to 50% of Guillain-Barré cases [8], which is a rare neurological
autoimmune disorder causing the immune system to attack the peripheral nervous
system leading to weakness, numbness, and tingling, and can eventually cause
paralysis [9].
Campylobacter jejuni
Campylobacter jejuni is considered to be responsible for ~80-90% [10] of the 95
million annual cases of Campylobacter-induced gastroenteritis worldwide [2].This is
exemplified by a surveillance study in the United Kingdom found that C. jejuni
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accounted for 93% of the Campylobacter infections out of 3,764 cases [11]. C. jejuni’s
infectious dose of fewer than 500 organisms [9] is generally lower than those of other
enteric bacteria including Salmonella typhmurium or pathogenic E. coli strains [12].
Antibiotic resistance in C. jejuni has increased over the last couple of decades
[13], leading the Center for Disease Control (CDC) to classify antibiotic resistant C.
jejuni as a “Serious Threat” to public health [14]. The U.S. Food and Drug
Administration (FDA) withdrew the final remaining fluoroquinolone approval for poultry
flocks in 2005, but the National Antimicrobial Resistance Monitoring System (NARMS)
surveillance has observed an increase of ciprofloxacin (a fluoroquinolone) resistance in
C. jejuni clinical isolates from 19.6% in 2006 to 25.3% in 2015 [15]. Since the rise of
fluoroquinolone resistance, when treatment against C. jejuni is necessary, macrolides
like azithromycin are now the drugs of choice since only 2.7% of C. jejuni clinical
isolates were resistant to azithromycin in 2015 [15]. While this demonstrates the issue
of rising antibiotic-resistance in C. jejuni in the developed world, it is also an increasing
issue in the undeveloped world where there are less regulations on antibiotic use.
Campylobacter coli
Campylobacter coli is the second most common Campylobacter species
associated with human infection [1]. The UK surveillance study previously discussed
found that C. coli was responsible for 7% of cases and it is considered to be responsible
for ~10% of all Campylobacter human infections worldwide [11]. C. coli also shares very
similar clinical manifestation of human infection as C. jejuni [11]. Although C. coli is
responsible for fewer human infections, NARMS reported the species has a higher rate
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of antibiotic resistance [15]. The 2015 Human Isolates Surveillance Report states that
39.8% of C. coli isolates were resistant to ciprofloxacin and 12.7% were resistant to
azithromycin [15]. Although C. coli is responsible for fewer clinical cases, the increase of
antibiotic resistance may suggest an association with lower rates of successful antibiotic
treatment than observed in C. jejuni.
Other Campylobacter Species
While significantly less frequent than C. coli or C. jejuni, other species of
Campylobacter have been reported to cause human disease [16]. NARMS reported
testing 46 (4% of study population) non-C. jejuni/C. coli Campylobacter species in 2015
[15]. Studies suggesting these “other species of Campylobacter” are increasing in
burden and importance in developing countries [8, 17]. For example, Campylobacter
upsaliensis was found to be present in 23% of Campylobacter stool isolates in South
Africa using filtration culture [18, 19]. In contrast, Irish and Canadian studies using
filtration culture and/or PCR detected C. upsaliensis in only 0.7 - 2.1% of stool
specimens [20-22]. Although Campylobacter is more often associated with livestock,
there are reports of pet-to-human transmission of C. upsaliensis from domestic dogs
and cats, a reservoir of C. upsaliensis [23-25].
There are reports of human campylobacteriosis caused by other Campylobacter
species, including C. concisus [26], C. sputorum [27], C. ureolyticus [28], and C.
hyointestinalis [29]. C. concisus, a colonizer of the human oral cavity, is suspected in
causing a primary barrier function defect leading to the onset of inflammatory bowel
disease [30, 31], and is associated with Crohn’s Disease in children [32].
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In light of new diagnostic testing techniques, Campylobacter epidemiological
studies are now able to detect Campylobacter incidences more readily with a wider net
for species detection [33]. Previous methods were highly selective for C. jejuni/C. coli in
comparison to other Campylobacters, suggesting these other Campylobacters may
have a higher incidence rate than previously considered [17].

Diagnostic Testing of Campylobacter
Current Clinical Diagnostics in Developed World
Laboratory diagnostics to identify Campylobacter infections are beginning to
expand to using culture-independent technologies, but culture-dependent
methodologies still dominate the field [1, 8, 34]. The clinical field primarily uses
techniques to target C. jejuni/C. coli species. The routine technique for culturing C.
jejuni or C. coli from feces utilizes selective media infused with multiple antibiotics and
sheep or horse blood [34]. Incubation at the human body temperature of 37C or the
chicken cecum at 42C in combination with decreased oxygen levels, and increased
carbon dioxide and nitrogen levels promote the growth of C. jejuni [34].
A major drawback to the culture-based methods is that Campylobacter detection
is sensitive to the fecal transport media and viability is affected between bowel
movement to actual fecal culturing [1, 35, 36]. A recent study provided a quantitative
estimate of C. jejuni/C. coli detection in fecal-derived cultures and viability losses of
Campylobacter-positive specimens in the commonly used Cary-Blair transport medium
[35]. The study results suggest poor stability of Campylobacter in Cary-Blair transport
media [36]. They observed a 94% loss of culturable C. jejuni when fecal samples spiked
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with C. jejuni and diluted in Cary-Blair medium were stored at 2-8C for 24 hours, and
C. jejuni was unable to be cultured at 48 or 96 hours [35]. This demonstrates how
difficult accurately culturing Campylobacter in a clinical setting can be.
In an attempt to more accurately detect Campylobacter, culture-independent
methods have been developed over the last two decades [37]. The use of immune and
nucleic acid-based methodologies are becoming increasingly routine for the fast
detection and identification of foodborne pathogens [38]. Enzyme immunoassay (EIA)based stool antigen tests are commercially available assays for Campylobacter
detection [39]. The EIA-based methodologies exploit antibody affinity for specific target
antigens found on the surface of Campylobacter cells [38]. The EIA is desirable due to
the relative simplicity of the protocol and speed of results [38], but there are conflicting
reports on its sensitivity although it is highly specific [39]. The nucleic acid-based
technologies, such as Polymerase-Chain Reaction (PCR), utilize the highly specific and
distinct nature of DNA or RNA sequences [38]. PCR primers for detecting
Campylobacter have been created to amplify specific regions of DNA allowing specific
detection of Campylobacter [33]. While these methodologies have their advantages,
there are still drawbacks.
Both EIA and PCR-based methodologies were primarily designed for C. jejuni or
C. jejuni and C. coli detection, thus excluding detection of all other Campylobacter
species [17, 33]. There have been conflicting reports on how sensitive and specific
enzyme immunoassay (EIA)-based stool antigen tests and nucleic acid-based tests are
in comparison to culture in children and adults [8, 37, 39]. Clinical labs have reported a
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high false positivity rate among the culture independent techniques, which has led to the
current gold standard for detection to be either culture-positive or both PCR and EIA
positive [8, 37]. This addition of culture-independent techniques is especially crucial
since a study that found culture-based methods only had a 37% sensitivity rate in over
500 tested samples [37].
Current Clinical Diagnostics for Studies in Developing Countries
A recently published Campylobacter study performed by the Etiology, Risk
Factors and Interactions of Enteric Infections and Malnutrition and the Consequences
for Child Health and Development study (MAL-ED), suggested that C. jejuni and C. coli
may not be the primary Campylobacter pathogens as previously considered in lowincome countries [17]. This MAL-ED case-control study revealed that of the 439 stool
samples tested 76.4% of the 216 positive Campylobacter detections were non-C.
jejuni/C. coli species [17]. Children experiencing dysentery were more likely to be
infected with C. jejuni/C. coli species than “other Campylobacters” [17]. The other
Campylobacters were more prevalent across all age groups than C. jejuni/C. coli with
older children bearing a higher burden of other Campylobacter, and other
Campylobacter are more likely to detected in an asymptomatic child [17]. The other
Campylobacters were also statistically just as likely as C. jejuni/C. coli species to cause
severe diarrheal episodes [17].
Researchers from the MAL-ED study also determined the current “standard”
methods for the detection of Campylobacter in feces in developing countries [33]. In
order to make this determination, the group compared commonly utilized culture,

7

enzyme immunoassay, and PCR techniques for Campylobacter detection sensitivity
and accuracy [33]. They ultimately recommend the use of quantitative-PCR (qPCR) “as
the preferred diagnostic modality for detection of Campylobacter infection for
epidemiologic studies in the developing world” [33]. The advantage of qPCR over PCR
is that the fluorescent labeling allows for the quantification of the amplified DNA region
[33]. This recommendation is based on results suggesting that qPCR can both
determine the presence and burden of infection, and can give species specific
information [33]. Although these results are dependent on primer choice [33]. For
example, the use of 16S rRNA gene will detect any Campylobacter species and
potentially identify the specific species but does require DNA sequencing and analysis
[33]. There are other Campylobacter-specific primers, but most are designed to detect
C. jejuni/C. coli strains [38]. The genomic plasticity contributes to the difficulty of
designing a single accurate and specific Campylobacter genus primer [38].

Overview of Campylobacter Metabolism
Campylobacter’s metabolism is still not fully understood but is known for some of
its distinctive metabolic traits [40]. Most Campylobacter are thermophilic bacteria that
grow preferentially between 42C (chicken body temperature) and 37C (human body
temperature), does not proliferate below 30C, but is able to survive and perform basic
metabolic functions in temperatures as low as 4C [41]. This ability to survive diverse
temperatures, pH, oxygen concentrations, and osmotic environments is what allows
Campylobacters to colonize a diverse range of animal hosts [1, 9, 10, 40, 42].
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The most notable metabolic property of C. jejuni is its non-glycolytic nature due
to its inability to catabolize glucose [10, 43]. Some strains of C. coli have been found to
perform glycolysis [40]. A few strains of C. jejuni have the genomic island that encodes
the enzymes required for fucose utilization and the chemotaxis receptors for it [44] but is
not widely possessed by most strains [40, 44]. The citric acid (TCA) cycle and
gluconeogenesis are required for biosynthesis of precursor substrates for lipooligosaccharides (LOS) and capsular polysaccharides [40]. Catabolism of amino acids,
keto acids, organic acids, and short chain fatty acids (SCFA) is the primary source of
energy production for Campylobacters growth [40]. C. jejuni prefers amino acids,
specifically serine, aspartate, glutamate, and proline for its carbon source, but some
strains can utilize asparagine and glutamine as well [40].
While C. jejuni is microaerophilic and does not use oxygen as a terminal electron
acceptor, it still runs the TCA cycle in the oxidative direction by utilizing the bifunctional
enzyme FrdABC complex [10]. Under strict microaerophilic conditions, FrdABC serves
as succinate dehydrogenase and as fumarate reductase to convert fumarate to
succinate [10]. C. jejuni also commonly utilizes formate, nitrate, and nitrite as alternative
electron acceptors [10]. It has been suggested that Campylobacters have a mechanism
for recognizing differences in the spatial distribution of specific SCFAs and other
metabolites to discriminate between different regions of the chicken (and potentially
other hosts) intestinal tract and exploits this to coordinate expression of genes
necessary for optimal colonization [45]. Research has shown that lactate (abundant in
the chick’s upper intestine) is associated with repression of catabolic gene expression,
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while acetate and butyrate (abundant in the chick’s lower intestine) is associated with an
increase in catabolic gene expression [45]. This suggests that there may be “cues” that
C. jejuni uses to colonize the human gastrointestinal tracts (GI).

Phase Variation
While Campylobacters have relatively small genomes (~1.7 Mb), they display
extensive genetic variations [5, 46]. C. jejuni’s genome contains a high prevalence of
hypervariable sequences consisting of homopolymeric tracts (HT) [5, 46]. These HTs
allow for C. jejuni to rapidly mutate and increase evolutionary adaptation by a process
known as Phase Variation (PV) [5]. Phase variation is a form of ON/OFF switches in
gene expression mediated by changes in the number of repeats in repetitive DNA
sequences [5]. These repetitive DNA sequences, known as simple sequence repeats
(SSRs), are repeats of the same DNA sequence directly adjacent to one another [47].
PV is the reversible change of these SSRs, while being characteristically stochastic,
high-frequency, reversible, and causes heritable phenotypic changes [5]. There are two
types of PV: 1) Translational PV occurs when the SSR is located in the open reading
frame leading to frameshift mutations, which routinely cause truncation of the protein
leading to the production of a non-functional protein product [46, 47]. 2) Transcriptional
PV alters the activity of a regulatory element (i.e. promoter) due to changes in repeat
number of an intergenic SSR [46, 47].
A recent study used an ‘omic based approach to analyze the distribution and
conservation of the “phasome” (putative and known SSR-driven PV genes) in
Campylobacter [47]. The study utilized the program PhasomeIt, a python-based tool for
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locating, classifying, and grouping phase variable SSRs in genomic collections [47], and
77 whole genome sequences from 14 Campylobacter species to identify new trends in
Campylobacter phasome [47]. Each strain had between 5-81 PV genes, and C. jejuni
(n=35) and C. coli (n=10) had means of 20 and 15 PV genes, respectively [47]. The
majority of the identified homologous PV genes across the genus have putative roles in
modification of the flagellin, or encode enzymes with roles in modification of the LOS,
capsule polysaccharide, or flagellum [47]. The flagella, LOS, and capsule have been
associated with roles in Campylobacter virulence [5]. Virulence is the organism’s ability
to infect a host and cause disease [48]. Virulence factors of an organism are the gene
products that help to i) invade the host, ii) cause disease, and iii) evade host defenses
[48]. The adaptative process of phase variation is able to genetically regulate virulence
factors and is advantageous for Campylobacter’s colonization of diverse hosts and
immune evasion [5, 46, 47].
A study on C. jejuni transcriptional and genetic adaption was able to identify
influential variants selected for during adaptation of a new host environment utilizing
whole genome sequencing and transcriptomics [46]. The study infected 14 human
volunteers with C. jejuni strain CG-8421, tracking transcriptional and genetic changes
between inoculum and human infection isolates [46]. The comparison of gene
expression was accomplished using RNA transcriptomes from three of the human
infected feces, the inoculum strain cultured on blood agar, Mueller-Hinton (MH) Agar,
and MH broth, and previously published transcriptomes of C. jejuni strain 81-176
colonizing the chicken cecum [46]. The comparison identified 39 core genes that are
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differentially regulated across host and colonization behavior. These genes are involved
in iron acquisition, inorganic phosphate uptake, and protection from peroxide stress
[46]. Interestingly, chuA, chuD (genes involved in hemin uptake), and cfrA (gene
involved in uptake of siderophores) were all upregulated >100 fold in human infection
verses chicken colonization [46]. ChuA is potentially a critical virulence factor for C.
jejuni as it is not required for chick colonization [49] but was found to have >1000-fold
expression increase in human infection [46].
The study identified variations in the genomic sequences of Campylobacter
populations by calling variants, a single nucleotide polymorphism (SNP), phase
variation (PV), or multiple nucleotide polymorphism (MVP) if it occurred in >25% of the
genomic population [46]. There were 48 unique genomic variants were identified, and
19 of the 28 PV poly G/C tracts in CG8421 genome varied in at least one of the human
infection populations [46]. Genetic variants of three genes with protein products with
roles in metabolism, iron/heme acquisition, and respiration were selected in all
population isolates [46].
Five of the volunteers experienced recrudescent infections allowing for the
comparison of acute and persistent infection variants [46]. Since the number of variants
did not increase over time during primary infection, but twice as many gene variants
were observed in the recrudescent population suggests there is an immediate and
consistent selection pressure during the primary infection [46]. Seven out of the eight
(identified by this study) flagella modification genes were associated with either acute or
persistent infection populations suggesting that flagellar modification plays a large role
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in Campylobacter virulence [46]. This study’s investigation of C. jejuni’s transcriptional
and genetic adaption in the human infection environment gave new insights to the
Campylobacter pathogenesis research field, including the significance of genetic
adaption and population selection during infection [46].

Human Microbiome and Colonocyte Metabolism
Understanding the environment being invaded when investigating
Campylobacter’s pathogenesis is critical for identifying links between Campylobacter’s
metabolism, virulence, and genetic adaption and the host environment. It is essential for
the mammal gut immune system to maintain the integrity of epithelial lining and other
host tissues, while detecting and destroying potential pathogens without needlessly
reacting to food, normal commensal microorganisms, and any other innocuous luminal
content [50]. The immune regulation/response of the gastrointestinal tract is required to
be highly sophisticated. The rapidly increasing research on the human microbiota has
revealed the immune system may play a role in balancing microbial communities
inhabiting human bodies [51].
The largest barrier delaying the understanding of specific immune functions or
cell types required for maintaining microbiota homeostasis in the colon is the difficulty of
defining what a “balanced” microbiota should be [51]. This is a challenging task because
these microbial communities are i) highly diverse, ii) differ between individuals, and iii)
shift with diet changes [51, 52]. Research suggests the immune system shapes the
microbiota to be beneficial in order to maintain homeostasis [53]. A beneficial microbiota
would aid in the digestion of nutrients that the host cannot breakdown such as complex
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carbohydrates [54], promote immune system development [55], and provide niche
protection against enteric pathogens [56].
Host mechanism research indicates colonic epithelial cells (colonocytes) have a
central role in shaping the microbiota [53, 57]. The colonic stem cells, located at the
base of the intestinal crypts, generate transit-amplifying cells by asymmetrical division
[58]. These transit-amplifying cells will eventually terminally differentiate into various
epithelial cell types including, colonocytes, enteroendocrine cells, or goblet cells [58].
Activation of epithelial differentiation requires a nuclear receptor known as peroxisome
proliferator activated receptor -  (PPAR-) [51]. PPAR- is primarily synthesized in the
differentiated cells of the epithelium of humans and rodents [59, 60]. PPAR- also
activates fatty acid metabolism resulting in mitochondrial -oxidation of long-chain and
SCFAs (Fig. 1a) [54, 61, 62]. The mature colonocytes primarily use mitochondrial oxidation, which consumes oxygen via oxidative phosphorylation [51]. Increasing
colonocyte oxygen consumption leads to a decrease in the amount of oxygen freely
diffusing from the epithelial surface into the lumen [51]. This decrease of oxygen partial
pressure to less than 1% or 7.6mmHg results in a condition termed epithelial hypoxia
[63]. Epithelial hypoxia is critical for maintaining anaerobiosis in the intestinal lumen
[63].
Anaerobiosis ensures the dominance of obligate anaerobic bacteria in the colonic
microbiota [64]. The adult human colonic obligate anaerobic community is
predominately comprised of members of the phyla Firmicutes and Bacteroidetes, which
include members that benefit the host with their broad spectrum of enzymes for
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complex carbohydrate hydrolysis [51]. In turn these obligate anaerobes assist with
maintaining the epithelial hypoxia since many members of the class Clostridia
(Firmicutes) encode enzymes to convert dietary fiber into butyrate [65], and butyrate
activates PPAR- signaling in the epithelial cells (Fig. 1a) [54, 62, 66].
Since the colonic epithelium and its metabolism may contribute to the immune
functions that maintain the shaping of the microbiota to a beneficial homeostasis [61],
an underlying defect in the immune functions that maintain the homeostasis may cause
a microbiota “imbalance” [53, 67]. This imbalance, known as dysbiosis, is commonly
associated with an increased abundance of facultative anaerobic bacteria [59, 68]. This
dysbiosis is detrimental to the host since facultative anaerobes, including members of
the phylum Proteobacteria, cannot produce fermentation products from fiber and will
consume other microbiota-derived fermentation products [69]. Dysbiosis is associated
antibiotic therapy [70], consuming a high-fat western style diet [71, 72], colorectal
cancer [73], inflammatory bowel disease [74], irritable bowel syndrome [75], and
necrotizing enterocolitis [76].
The “oxygen hypothesis” suggests a disruption in anaerobiosis, mediated by the
ability of facultative anaerobes to respire oxygen, would induce a shift in the microbial
community from obligate to facultative dominance (Fig. 1b) [74]. Research on the
impact of antibiotic therapies on the microbiome has provided valuable information on
mechanisms that disrupt intestinal microbiota homeostasis [51]. Antibiotic treatments
deplete fermentation product producers leading to decreased availability of butyrate,
propionate, acetate, and other fermentation products [51]. In murine models, SCFAs are
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absorbed into the colon where they will bind to G protein-coupled receptors, and inhibit
intestinal inflammation by maintaining the population of regulatory T-cells in the mucosa
[55, 77, 78]. The depletion of butyrate reduces PPAR- signaling in human and murine
epithelial cells [55, 79]. Silencing of PPAR- signaling leads to the reduction of the
number of regulatory T-cells in the murine mucosa [80]. Therefore, antibiotic treatment
increases the inflammatory state of the colonic mucosa [61], and the inflammatory
signals shifts the metabolism of terminally differentiated surface colonocytes toward
anaerobic glycolysis (Fig. 1b) [81, 82].
Anaerobic glycolysis metabolism is characterized by its high consumption of
glucose, abundant production and release of lactate, and low oxygen consumption [51].
The colonocyte metabolic shift to anaerobic glycolysis leads to the loss of epithelial
hypoxia due to the lack of high oxygen consumption causing an increased concentration
of oxygen to diffuse into the lumen [51, 59]. The reduction of PPAR- signaling by the
depleted concentration of butyrate leads to an increase of inducible nitric oxide
synthase (iNOS) synthesis causing nitric oxide productio (Fig. 1b) [61]. The nitric oxide
is converted to nitrate in the intestinal lumen [83], and contributes to the expansion of
Proteobacteria when used as a terminal electron acceptor for anaerobic respiration [68,
83].
Excessive epithelial repair drives the accumulation of dividing transit-amplifying
cells that cause crypt elongation, known as colonic crypt hyperplasia, a common feature
of ulcerative colitis [84]. Colonic crypt hyperplasia leads to the thinning of the mucus
layer by reducing the number of terminally differentiated epithelial goblet cells, which is
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the primary producer of the mucus layer [58]. The reduced number of terminally
differentiated epithelial cells leads to reduced production of PPAR- and activation of
mitochondrial -oxidation of fatty acids, which decreases epithelial hypoxia [84].
Additionally, low PPAR- synthesis increases intestinal permeability (“leaky gut”) in the
rat colitis model [85]. This is caused by PPAR- regulation of tight junction molecules in
the epithelial cells [86].
An important function of the colonic surface is utilizing niche protection against
facultative anaerobic enteric pathogens by limiting the luminal availability of hostderived respiratory electron acceptors and carbon sources [51, 56]. Some species are
able to overcome niche protection by the use of their virulence factors [87]. Salmonella
enterica triggers severe acute intestinal inflammation with its virulence factors, which
induces neutrophil migration into the intestinal lumen causing the depletion of both
Clostrida spp. and their SCFA fermentation products [88, 89]. Additionally, the
respiratory burst of phagocytes generates electron acceptors such as nitrate and
tetrathionate [90]. S. enterica outcompetes obligates by consuming microbiota-derived
fermentation products and host-released lactate as carbon sources [88]. Although
Campylobacter’s invasion/colonization mechanism in human’s is not well understood, it
is known for inducing severe acute intestinal inflammation [5]. This process could
potentially mirror S. enterica’s method of depleting Clostrida spp. and their SCFA
fermentation products, which are compatible with Campylobacter’s catabolism [40].
Another enteric pathogen, Citrobacter rodentium, is a mouse pathogen
frequently studied as a model for virulence mechanisms used by human attaching-and-
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effacing pathogens such as enteropathogenic E. coli or enterohemorrhagic E. coli [91].
C. rodentium uses virulence factors to attach to the colonic surface and cause epithelial
injury to induce colonic crypt hyperplasia by excessive epithelial repair [91]. C.
rodentium will utilize the increased oxygen concentration and microbiota-derived
products to compete with the commensal gut microbiota [91]. Campylobacter is known
to attach to colonic surfaces and is associated with epithelial damage and villous
blunting [7], which could indicate pathogenic mechanisms similar to C. rodentium.
These examples demonstrate the importance of host-microbe and microbiota-microbe
interactions when examining Campylobacter human pathogenesis.
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CHAPTER TWO – INTRODUCTION
Malnutrition is a complex condition responsible for approximately 45% of deaths
in children under five years old [92]. Chronic pediatric malnutrition has multiple causes,
including food insecurity, recurrent enteric infections, gut dysbiosis, and impaired
immunity [93]. The interrelated nature of these conditions makes it difficult to
distinguish impaired immunity and increased susceptibility from persistent enteric
infections and gastrointestinal dysbiosis [94]. Chronic pediatric malnutrition can then
subsequently lead to growth faltering, cognitive impairment, and/or other long-term
pathologies [95].
In the example of recurrent enteric infections, continuous exposure to
gastrointestinal pathogens can lead to prolonged intestinal inflammation, which can
further lead to the development of Environmental Enteric Dysfunction (EED) [93]. This
disorder is characterized by villous blunting and decreased intestinal integrity, which
drives reduced nutrient absorption and is associated with stunting (low height-for-age)
[93].
Campylobacter was overlooked as a serious public health issue for many years
primarily because the difficulty of culturing and previous lack of PCR techniques for
diagnosis in combination with the frequently asymptomatic nature of Campylobacter in
the developing world [96]. In 2013, a controlled etiological study of moderate-to-severe
diarrhea in children in Asia and Africa designed to comprehensively identify the
pathogen-specific etiology and burden of disease associated with each pathogen the
Global Enteric Multicenter Study (GEMS) was published and highlighted the prevalence
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of Campylobacter infections in these environments [97]. GEMS occurred between
December 2007 and March 2011, in seven different sites across Africa and Asia, and
enrolled 9439 children with moderate-to-severe diarrhea and 13129 children as
asymptomatic controls all between the ages of 0-59 months [97]. The cases and
controls were all matched for age, sex, and village, and the detection of Campylobacter
by culture using selective blood agar plates incubated at 42°C [97]. They found that
Campylobacter was in the top five pathogens associated with burden of diarrhea in
three out of the seven sites [97].
To identify the specific enteric pathogens that may cause EED, the Etiology, Risk
Factors and Interactions of Enteric Infections and Malnutrition and the Consequences
for Child Health and Development study (MAL-ED) worked to identify which infections
most often correlated with impaired physical growth, cognitive development, and
immunity in pediatric populations in the developing world [98]. To accomplish this, the
investigators monitored children until two years of age from eight geographically distinct
sites known to have high rates of malnutrition to determine which exposures correlated
with gastrointestinal disease and ultimately which may lead to decreased growth and
development [99]. Not surprisingly, several common enteric pathogens significantly
correlated with diarrhea in the first year of life, including (in order of prevalence)
norovirus GII, rotavirus, Campylobacter spp., Astrovirus, and Cryptosporidium spp.
Similarly, Campylobacter spp., norovirus GII, rotavirus, Astrovirus, and Shigella spp.
were associated with diarrhea in the second year of life [98]. While Campylobacter was
the third pathogen most often associated with diarrhea in the first year of life, it
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increased to the most often associated in year two. The predominance with which
Campylobacter associated with diarrhea occurred across all sites [100] and another
study reported asymptomatic Campylobacter infection can result in increased intestinal
permeability and stunted growth [101].
To begin characterizing these events, groups have examined both the host and
bacterial responses to infection using human clinical samples, including those obtained
from human feeding studies [46], and have leveraged various animal models of disease
[6, 102]. These studies have demonstrated that Campylobacter-induced disease is likely
a multifactorial process dependent on the host immune response, the host microbiota,
host nutritional status, and bacterial factors.
As host and bacterial characteristics likely differ between populations in
industrialized nations and LMICs, it is going to be important to conduct multiple studies
using well characterized clinical groups within each population, including specifically
examining samples from pediatric subjects. To that end, we obtained pediatric fecal
samples collected during a case-controlled study of acute diarrheal disease in
Colombia, a middle-income country, and performed untargeted, omics-based analyses
on the samples [103]. These methods allowed us to begin examining the impact
Campylobacter infection has on the gastrointestinal environment of pediatric
populations in middle-income countries.
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CHAPTER THREE – MATERIALS AND METHODS
Subject Recruitment and Data Collection
Study Site
As previously described [103], the study was conducted in the Bucaramanga,
Colombia metropolitan area. Bucaramanga is the capital city of the Santander
department of Colombia. This city includes four municipalities, a population of 525,000,
and 90% availability of basic utilities including those for water, electricity, gas,
telephone, and garbage collection frequency of three times a week [103]. The coverage
of pediatric hospital beds in this region is 0.48 per 1000 for children under 12 years of
age [103]. The under-5 mortality rate in Colombia was 5.26 per 100,000 children in
2010, with acute diarrheal disease (ADD) being the third leading cause of morbidity
among children less than five years of age in Santander, Colombia [103].
Subject Recruitment
Samples were collected during a study designed as a prospective, matched-forage, case-control study to determine the etiology of ADD in children from two weeks to
59 months of age in the Bucaramanga metropolitan area, Colombia [103]. The ADD
study was approved by Institutional Review Board, Vanderbilt University School of
Medicine (IRB number 130327). From August 2013 to December 2014 subjects were
recruited from emergency, inpatient, and outpatient facilities of major medical
institutions including Unidad Intermedia Materno Infantil Santa Teresita (UIMIST),
Centro de Salud el Rosario, Fundación Oftalmológica de Santander Carlos Ardila Lulle
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(FOSCAL), Hospital Local del Norte, Clínica Materno Infantil San Luis, and Hospital San
Juan de Dios de Floridablanca in the Bucaramanga metropolitan area, Colombia.
After informed written consent was obtained, an interview questionnaire was
administered to the subject’s parents or guardians and recorded in Spanish by trained
clinical researchers at enrollment and two and six weeks after. Data collected included
demographics, medical history, epidemiological factors, socioeconomic factors,
nutrition, education, immunization history, water sources, and housing. In some cases,
information was obtained about clinical manifestations specifically about characteristics
of diarrhea, vomiting, abdominal pain, and dehydration. Access to the metadata and
fecal samples was approved by and conducted under the University of Tennessee
Institutional Review Board protocol #IRB-17-03795-XM.
Sample Collection
Stool samples were collected from children age two weeks to 59 months on
either the day of enrollment or up to one-week post-enrollment from August to
December 2014. Samples were collected in sterile disposable plastic containers and
transported to the Laboratorio de Investigaciones Biomédicas y Biotecnológicas (LIBB)
at the Universidad de Santander, Bucaramanga, Colombia within four hours. Once
samples were examined for color, consistency, presence of blood and/or mucus,
aliquots were made and divided into those to be immediately tested and those for
storage at -20C and -80C [103].
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Detection of Gastrointestinal Pathogens
The samples were tested for viral, parasitic, and bacterial infections at the
Laboratorio de Investigaciones Biomédicas y Biotecnológicas (LIBB) at the Universidad
de Santander, Bucaramanga, Colombia. Trained clinical technicians tested the fecal
samples for Adenovirus, Astrovirus, Norovirus, Rotavirus, Sapovirus, Entamoeba
histolytica, Giardia lamblia, Cryptosporidium spp., Campylobacter spp., Salmonella
spp., Shigella spp., Yersinia spp., enteroaggregative Escherichia coli (EAEC), diffuseadhering E. coli (DAEC), enteropathogenic E. coli (EPEC), enteroinvasive E. coli
(EIEC), enterotoxigenic E. coli (ETEC), and shigatoxigenic E. coli (STEC) [103].
Detection of Virial and Parasitic Pathogens
Described previously [103], RNA extracted from human stool samples were used
for detection of Norovirus, astrovirus, and Sapovirus, while extracted DNA was used for
Adenovirus detection. Detection of Norovirus GI and GII was conducted according to
the US CDC protocol: GI/GII Norovirus Multiplex (TaqMan Life Technologies, Carlsbad,
USA) real-time PCR (RT-PCR) Assay. Astrovirus and Sapovirus detection were
conducted from isolated RNA according to the United States Center for Disease Control
(CDC) protocol: Astrovirus/Sapovirus Duplex Real-Time (TaqMan) RT-QPCR Assay.
RNA preparation from astrovirus and Sapovirus negative and positive human stool
samples were negative and positive controls in qRT-PCR, and water was non-template
control. Adenovirus detection from DNA isolated from stool samples was performed by
qPCR. DNA samples obtained from adenovirus negative and positive human stool
samples were used as negative and positive controls, respectively. Water was used as
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a non-template control. Identification of Rotavirus was done by the Rotavirus Stool
Antigen Detection ELISA assay according to manufacturer’s instructions (Diagnostic
Automation, Calabasas, USA).
All stool samples were processed for detection of Giardia lamblia, Entamoeba
histolytica, Entamoeba dispar, and Cryptosporidium antigens by direct ELISA
(Diagnostic Automation, Calabasas, USA) following manufacturer’s instructions.
Clinical Detection and Identification of Escherichia coli
E.coli screening and identification protocol is previously described [103]. Stool
samples were plated onto MacConkey (Merck, Darmstadt, Germany) agar. Isolates that
were positive for lactose fermentation were used to inoculate Eosin Methylene Blue
(EMB) agar (Merck, Darmstadt, Germany). If isolates had metallic shine on EMB agar
plates, they would then inoculate SIM medium (Merck, Darmstadt, Germany). Isolates
positive for motility and indole production, but negative for sulfide production would be
confirmed as E. coli by uidA DNA amplification by PCR. A random subset was selected
for API20E testing for further confirmation. Confirmed E. coli isolates were stored at 80°C in Luria broth (LB) (Scharlau, Sentmenat, Spain) supplemented with 15% glycerol
(Merck, Darmstadt, Germany).
The bacterial stocks of the isolates were inoculated on LB plate (Scharlau,
Sentmenat, Spain) and cultured at 37°C overnight. Harvested cultures were suspended
in one-milliliter sterile water, vortexed for 10 seconds, and centrifuged at maximum
speed for two minutes. The supernatants that contained bacterial DNA were incubated
for five minutes at 95°C on a thermocycler and used as DNA template in multiplex
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polymerase-chain reaction (mPCR). The mPCR was designed to detect six wellestablished pathogenic E. coli pathotypes including diffusely adherent E. coli (DAEC),
enteroaggregative E. coli (EAEC), enteroinvasive E. coli (EIEC), enteropathogenic E.
coli (EPEC), enterotoxigenic E. coli (ETEC), and Shiga-toxin producing E. coli (STEC).
The mPCR was divided into four reaction mixes with primers targeting specific virulence
genes of each pathotype: reaction mix 1 targets lngA, bfpA, and stx2 genes; reaction
mix 2 targets eae, daaE, ipaD, and aaiC genes; reaction mix 3 targets ipaH, escN,
aggR, and estA genes; reaction mix 4 targets elt and stx1 genes. The strains used as
controls in the mPCR included the following: negative control DH5𝛼 E. coli, negative
control TOP10F’ E. coli, C1845 DAEC, JM221 EAEC, EC-12 EIEC, E2348/69 EPEC,
E9034A ETEC, and 2060-004 EHEC [104]. In each 25 𝜇l mPCR reaction, we add 21 𝜇l
Platinum Blue PCR SuperMix (Life Technologies, Carlsbad, USA), 2 𝜇l DNA template,
and 2 𝜇l primer mixes specifically indicated above. The final concentration of each
primer in mPCR reaction was 0.4 𝜇M. The thermocycling was set as 94°C for 5 minutes,
40 cycles of denaturing at 94°C for 30 seconds, annealing at 58°C for 30 seconds, and
extension at 72°C for 60 seconds, and final extension at 72°C for 5 minutes. The
annealing temperature for reaction 4 was set at 60°C to increase PCR specificity. The
PCR products were loaded onto a 2.0% agarose gel containing SYBR safe DNA gel
stain (Life Technologies, Carlsbad, USA) with DNA ladder, used electrophoresis to
separate DNA bands, and visualized under UV exposure.
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Clinical Detection of Shigella, Salmonella, and Yersinia spp.
Screening protocol of Shigella, Salmonella, and Yersinia spp. is previously
described [103]. Briefly, stool samples were used to inoculate Salmosyst broth (Merck,
Darmstadt, Germany) with supplements to select for Shigella and Salmonella species.
The bacteria able to grow in the selective media were subsequently cultured on
Salmonella-Shigella (SS) agar (Scharlau, Sentmenat, Spain) for isolation. Alternatively,
CESY Broth (Merck, Darmstadt, Germany) was used for recovery of Yersinia species
from stool samples, and subsequently cultured on CIN-Agar (Merck, Darmstadt,
Germany) for further selection of Yersinia species. All incubation temperatures and
times were 37°C for 24 hours.
Clinical Detection of Campylobacter
Campylobacter was detected by bacterial isolation on Campylosel agar
(Biomerieux, Marcy-l'Étoile, France) and confirmed through biochemical testing using
API CAMPY (SKU#20800, Biomerieux, Marcy-l'Étoile, France) [103] and quantitative
PCR (qPCR) testing as previously described [33]. Briefly, human stool samples were
diluted 1:10 in DEPC-treated water (Life Technologies, Carlsbad, USA), vortexed, and
centrifuged. DNA was extracted using a QIAamp® DNA stool mini kit (Qiagen,
Valencia, CA) and stored at −20°C until use. A qPCR assay was developed using a
previously described assay for C. jejuni/C. coli on the CFX96 Touch™ Real-Time PCR
Detection System (Bio-Rad, Hercules, California, USA) [105]. Each well included a
25 µl reaction mixture with 1 µl of DNA sample, 12.5 µl of TaqMan® environmental
master mix, 9 µl of nuclease free water, 1 µl of each primer of cadF-Forward
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“CTGCTAAACCATAGAAATAAAATTTCTCAC” and cadF-Reverse
“CTTTGAAGGTAATTTAGATATGGATAATCG” at a final concentration of 0.4 µM, and
0.5 µl of cadF-Probe “[HEX]-CATTTTGACGATTTTTGGCTTGA-[BHQ2]” at a final
concentration of 0.2 µM. The cycling conditions were as follows: 95°C for 10 min,
followed by 45 cycles of 95°C for 15 s and 55°C for 1 min.

Preparation of Fecal Samples for Study
Classification of Cohorts for this Study
The inclusion and exclusion criteria for this study’s subjects is shown in table 1. The
subjects for this study were originally divided into 2 groups:
1) “Campylobacter infected” – these fecal samples were positive for Campylobacter
by qPCR identification (n=20).
2) “Campylobacter uninfected”– these fecal samples were negative for
Campylobacter by qPCR identification (n=20).
In order to control for presence of acute diarrheal disease in some of our
“Campylobacter uninfected” subjects, the cohorts were divided again:
1) “Campylobacter infected - symptomatic” or “CIS” – these fecal samples were
positive for Campylobacter by qPCR identification and presented with diarrhea
(n=14).
2) “Campylobacter infected - asymptomatic” or “CIA” – these fecal samples were
positive for Campylobacter by qPCR identification but presented without diarrhea
(n=6).
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3) “Campylobacter uninfected - symptomatic” or “CUS” – these fecal samples were
negative for Campylobacter by qPCR identification but presented with diarrhea
(n=8).
4) “Campylobacter uninfected - asymptomatic” or “CUA” – these fecal samples were
negative for Campylobacter by qPCR identification and presented without
diarrhea (n=12).
DNA Extraction from Fecal Samples
Total microbial DNA was isolated from feces using the DNeasy PowerSoil Kit
(QIAGEN Sciences Inc. Germantown, MD) following the manufacturer’s protocol by
thesis author. DNA was stored at -20°C until 16S rRNA gene amplification.
Generation and Sequencing of 16S rRNA Gene Amplicon Libraries
Primers targeting the V3-4 region of the 16S rRNA gene were used to create a
single amplicon of approximately 460 bp (16S Amplicon PCR Forward Primer: 5'CCTACGGGNGGCWGCAG-3’ and 16S Amplicon PCR Reverse Primer: 5'GACTACHVGGGTATCTAATCC-3’) according to the Illumina 16S Metagenomic
Sequencing Library Preparation Guide. Once the library was quantified and normalized,
it was pooled and sequenced on an Illumina MiSeq using v3 600 cycle kit. The
generation and sequencing of the 16S rRNA gene amplicon libraries were performed by
Veronica Brown in the University of Tennessee Genomics Core facility with assistance
from thesis author.
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Extraction of Fecal Metabolites
Extraction of metabolites from fecal samples was performed under a biological
safety hood by thesis author. A 0.1 gram sample was prepared by adding 0.650 mL of
Metabolic Extraction Solvent (MES) (20:40:40 H20:ACN:MeOH + 0.1 M Formic acid)
and mixing thoroughly before adding another 0.650 mL of MES and chilling at -20°C for
20 minutes. Samples were subsequently centrifuged (4°C at 13,500 rpm) and the
supernatant was transferred to a fresh microcentrifuge tube and stored at 4°C. The
resulting pellet was resuspended in 0.2 mL of MES and chilled at -20°C for 20 minutes
before centrifugation and transfer of the supernatant to a fresh microcentrifuge tube.
The sample tubes were immediately put on ice and transported to the Biological and
Small Molecule Mass Spectrometry Core (BSMMSC) of the University of Tennessee –
Knoxville. Once at the BSMMSC, the supernatant was then dried under nitrogen and
the resulting pellet was resuspended in 0.300 mL of milliQ H 2O before being transferred
to autosampler vials.
Ultra-High-Performance Liquid Chromatography Tandem Mass Spectrometry
(UHPLC–MS/MS) Analysis of Fecal Metabolites
The Generation of fecal metabolomes was performed by the Biological and Small
Molecule Mass Spectrometry Core of the University of Tennessee – Knoxville. Samples
were separated on a Phenomonex Synergi Hydro RP, 2.5 um, 100 mm x 2.0 mm
column at 25˚C. Mobile phase elution of metabolites were (A) 97:3 Methanol to Water
with 11 mM Tributylamine and 15 mM Acetic acid and (B) 100% Methanol. The gradient
used for mobile phase A during the 25-minute method with a flow rate of 0.2 mL/minute
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was 100% at minute zero, 80% at minute 5, 45% at minute 13, 5% at minute 15.5,
100% at minute 19 and 25, while the mobile phase B gradient equalized the
percentage. The Exactive Plus Orbitrap used an electrospray ionization (ESI) probe
operating in negative mode with a scan range of 72-1000 m/z.
Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) Analysis of Fecal
Micronutrients
The ICP-MS analysis was performed by the Spectroscopy and Biophysics Core
of the University of Nebraska, Lincoln. The fecal samples were weighed and suspended
in 1 mL of nitric acid (70% w/v). After overnight digestion at 65°C, the tubes were
cooled, loaded in triplicate into 96-well plates, and diluted 20-fold with a solution of 50
ppb Ga in 2% nitric acid. Counts for cobalt, chromium, copper, iron, manganese,
molybdenum, selenium, and zinc were normalized using this internal standard and were
converted to concentrations using an external calibration curve. The instrument setup
and acquisition method for ICP-MS were conducted as previously described [106].

Statistical Analyses
Epidemiological Analysis of Subject Data
Descriptive statistics were generated for all clinical and demographic variables.
For continuous variables, the association with being a Campylobacter case was
determined by t-test or the non-parametric equivalent, the Mann-Whitney U-test.
Categorical variables were analyzed with chi-square tests, with the exception of Fisher’s
exact tests were used when expected cell counts were less than five. Wilcox two-
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sample t-tests, Odds ratios, 95% confidence intervals, and p-values were determined
with significance inferred at a p-value < 0.05.
Analysis of Fecal Microbiomes
The amplicon sequencing reads were analyzed using mothur, an open source
and expandable software [107]. Sequencing and PCR errors were first reduced by
combining forward and reverse reads and scoring sequencing alignment, followed by
alignment of unique sequences to the SILVA 16S rRNA gene reference database
(version 132), which were then clustered into the corresponding operational taxonomic
units (OTUs) in the SILVA database.
To improve analytic results, data filtering was used to identify and remove
features (taxa in this case) that are unlikely to be of use when modeling the data [108].
These taxa are determined by either filtering based on abundance levels (minimum
counts) across samples (prevalence) or using minimum count cutoff based on their
mean and median values by the program [108]. Taxa with constant or less variable
abundances are crucial for comparative analysis and are filtered based on their interquantile ranges, standard deviations or coefficient of variations. By default, taxa having
zero counts across all the samples, or that only appear in one sample will be removed
from further analysis [108].
In order to ensure proper filtration, many settings were tested. The results shown
in the following chapter were produced using a low count filter with the minimum count
set to 4 and a prevalence in samples set to 20%. While in appendix results for settings
using a low count filter with the minimum count set to 2 and 6 and a prevalence in
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samples set to 10% and 25% are available. The low variance filter settings shown in the
results section data/figures were to remove 10% based on the inter-quantile range. After
filtration, 138 features were still remaining. In appendix, results from other low variance
filter settings can be viewed. These settings include removal of 15% based on interquantile range.
To normalize, the data were rarefied to the minimum library size (Fig. 2). No
dating scaling or transformation was performed for any results shown in the results
section. In the appendix, results from other normalization settings can be viewed. These
settings include total sum scaling and relative log expression.
R or MicrobiomeAnalyst [108] were used for OTU and population-level analyses,
which determined whether any OTUs were differentially represented between the
samples. ANOSIM or PERMANOVA were used to determine whether statistically
significant differences existed between the microbial communities in infected and
uninfected samples. Briefly, a Mann-Whitney U-test was performed to compare the
bacterial taxa present in the two groups and the p-values were adjusted for multiple
comparisons using the Benjamini and Hochberg False Discovery Rate (FDR) and
significance inferred at p < 0.05. Additionally, visualizations of the different taxa between
the groups were created using the linear discriminant analysis effect size (LEfSe) [109].
Analysis of Fecal Metabolomes
Samples were normalized by weight prior to inputting data into MetaboAnalyst, a
statistical, functional and integrative analysis of metabolomics data [110]. Since data
containing zeros or missing variables will cause difficulties in downstream analyses,
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these were were replaced with the small value of 4.431321 in the metabolomic data.
This value is half of the minimum positive values in the original data, which is assumed
to be the detection limit. The assumption of this approach is that most missing values
are caused by low abundance metabolites (i.e. below the detection limit) [110].
For multi-group analysis, MetaboAnalyst provides one-way Analysis of Variance
(ANOVA). While ANOVA only tells whether the overall comparison is significant or not, it
can be followed by post-hoc analyses in order to identify which two levels are different
[110]. MetaboAnalyst provides two most commonly used methods for this purpose Fisher’s least significant difference method (Fisher’s LSD) and Tukey’s Honestly
Significant Difference (Tukey’s HSD). ANOVA and post-hoc analyses were performed
with significance inferred at a p-value < 0.05.
Principal Component Analysis (PCA), an unsupervised method aiming to find the
directions that best explain the variance in a data set (X) without referring to class labels
(Y) [111], was performed using the prcomp package and requiring the R script
‘chemometrics.R’ in MetaboAnalyst [110]. The data in the PCA are summarized into
fewer variables called scores which are weighted average of the original variables, and
the weighting profiles are called loadings [111].
Another analysis utilized from MetaboAnalyst [110] is the Partial Least Squares Discriminant Analysis (PLS-DA). PLS is a supervised method using multivariate
regression techniques to extract the information, via linear combination of original
variables (X), that can predict the class membership (Y) [111]. A permutation test was
performed to assess the significance of class discrimination, and in each permutation, a
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PLS-DA model was built between the data (X) and the permuted class labels (Y) using
the optimal number of components determined by cross validation for the model based
on the original class assignment [112].
MetaboAnalyst supports two types of test statistics for measuring the class
discrimination based on: 1) prediction accuracy during training, and 2) separation
distance based on the ratio of the between group sum of the squares and the within
group sum of squares (B/W- ratio). The class discrimination cannot be considered
significant from a statistical point of view, if the test statistic is part of the distribution
based on the permuted class assignments [110]. Two variable importance measures in
PLS-DA are: 1) Variable Importance in Projection (VIP) is a weighted sum of squares of
the PLS loadings taking into account the amount of explained Y-variation in each
dimension [111], and 2) based on the weighted sum of PLS-regression. The weights are
a function of the reduction of the sums of squares across the number of PLS
components [111]. VIP scores are calculated for each of the components and when
more than components are used to calculate the feature importance, the average of the
VIP scores are used [110].
The sparse PLS-DA (sPLS-DA) algorithm can be used to produce robust and
easy-to-interpret models by reducing the number of metabolites in high-dimensional
metabolomic data [113]. Also controlling the number of components in the model and
the number of variables in each component, the sparseness of the model can be
controlled [113].
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Random Forest is a supervised learning algorithm suitable for high dimensional
data analysis by using an ensemble of classification trees, each of which is grown by
random feature selection from a bootstrap sample at each branch [110]. Random Forest
analysis was used to detect the impact of different metabolites between groups [114].
Also, Random Forest provides other useful information such as OOB (out-of-bag) error,
variable importance measure, and outlier measures [110]. Significant features identified
by Random Forest, and are ranked by the mean decrease in classification accuracy
when they are permuted [110]. Additionally, all t-tests were performed with significance
inferred at a p-value < 0.05.
Analysis of Micronutrient Profiles
Differences between infected and uninfected groups were detected using the
ROUT method to identify outliers with a Q = 0.1, then differences between infected and
uninfected cohorts were identified using an unpaired t-test (GraphPad Prism Software,
La Jolla California USA) and significance inferred at a p-value < 0.05.
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CHAPTER FOUR – RESULTS
Characteristics of Subjects
This study was conducted using fecal samples from 40 children under the age of five
years old from Bucaramanga, Colombia metropolitan area. The inclusion and exclusion
criteria for this study’s subjects is shown in Table 1. The subjects for this study were
originally divided into 2 broader cohorts: i) “Campylobacter infected” – these fecal
samples were positive for Campylobacter by qPCR identification (n=20), and ii)
“Campylobacter uninfected” – these fecal samples were negative for Campylobacter by
qPCR identification (n=20). These cohorts will be referred to as “infected” and
“uninfected” from this point on.
To control for presence of acute diarrheal disease in some of our “Campylobacter
uninfected” subjects, the cohorts were divided again into two. These cohorts include the
symptomatic/asymptomatic status of the subject: CIS: “Campylobacter infected symptomatic” (n=14), CIA: “Campylobacter infected - asymptomatic” (n=6), CUS:
“Campylobacter uninfected - symptomatic” (n=8), and CUA: “Campylobacter uninfected
- asymptomatic” (n=12). These groups will be referred to as individually CIS, CIA, CUS,
and CUA or as “the four cohorts” from this point on, except in appendix 2 where they
are referred to as 1, 2, 3, and 4, respectively.
The sociodemographic information is included in Table 2 for the “infected” and
“uninfected” cohorts. The age group 12 to 24 months was the only variable that
significantly differed between the two cohorts (p-value = 0.048). The mean and median
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age for all subjects were 21.2 and 16.28 months, respectively, and contained 65%
female and 70% mestizo participants. The sociodemographic information for the four
cohorts is shown in Table 3. None of the variables were found to be significantly
different between the four cohorts by the Kruskal-Wallis test.

Clinical Symptoms of Subjects
The Wilcoxon two-sample t-test revealed that the Campylobacter infected cohort
had a significantly longer number of days experiencing diarrhea than the Campylobacter
uninfected cohort (p = 0.030), and also experienced more diarrheal episodes in a 24hour period (p =0.043). Although no significant differences were detected for the
presence of fever, vomiting, diarrhea, bloody stool, mucus, or abdominal pain, the
clinical symptoms for each patient were recorded and are shown in Table 4. Due to the
low subject numbers in the four cohorts, clinical symptom analysis was not performed.

Environmental Exposures and Campylobacter Infection
To determine whether certain environments correlate with Campylobacter
infection, we examined for associations of each group with various exposures. The only
significant correlation that was found was that children in the uninfected cohort were
more likely to have had exposure to birds in the week prior to enrollment in the study
(Table 5). This is somewhat surprising since birds are a natural host for
Campylobacter. In contrast, children exposed to cats trended toward infection with
Campylobacter than children who were not exposed (Table 5).
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Other Bacterial and Viral Pathogens Detected in Subject Samples
In terms of pathogen manifestations, 100% of the Campylobacter infected
samples were positive for Campylobacter infection. The Campylobacter uninfected
subjects were positive for other pathogens 15% of the time, while 85% of the
Campylobacter uninfected samples were negative for the tested bacterial or viral
infections (Table 6). Although co-infections were observed in both cohorts, no
correlations between any specific pathogen and cohort, aside from Campylobacter, was
identified. Children with Campylobacter infection were approximately five times more
likely to be colonized by non-pathogenic (commensal) E. coli than the uninfected
children, but pathogenic enteroaggregative E. coli colonization occurred in 10% of the
samples in each cohort. Table 7 shows the bacterial and viral pathogens detected in all
4 cohorts. The most interesting observation being that CIS has the highest number of
co-infections (5), while cohorts CIA and CUA only have 1 each (Table 7).

Microbiome Analysis
Analysis of alpha-diversity (the diversity within a sample based on richness and
evenness) showed no significant differences in Chao1, Shannon diversity index, or
species richness between infected and uninfected cohorts (p-value=0.18744) (Fig. 3A).
When analyzing the four cohorts for alpha-diversity, no significant differences were
detected (p-value=0.327) (Fig. 4). Similarly, the beta-diversity (the difference in
taxonomic abundance profiles between the cohorts) were analyzed by principal
coordinate analysis (PCoA) and no significant differences in the microbiome were

39

detected when comparing infected and uninfected groups (p-value=0.074) (Fig. 3B) or
among all four cohorts (p-value=0.227) (Fig. 5).
Linear discriminant analysis (LDA) effect size (LEfSe), an analysis that
characterizes differences between two or more sample groups with an emphasis on
statistical significance and biological relevance using an algorithm for High-Dimensional
biomarker discovery and explanation that identifies genomic features, was used to
identify bacterial taxa that differed between infected and uninfected groups. First, LEfSe
utilizes the non-parametric factorial Kruskal-Wallis (KW) sum-rank test for differential
abundance analysis, followed by determining biological relevance by using the
(unpaired) Wilcoxon rank-sum test, and lastly applying the Linear Discriminant Analysis
to estimate the effect size of each differentially abundant taxon.
As expected, the only statistically significant family in infected children was
Campylobacteraceae (LDA= 2.76; p=0.004). Although Enterobacteriaceae exhibited the
largest effect size in uninfected children, it was not statistically significant (LDA= -3.27;
p=0.148). Using a univariate statistical comparison of the groups, only the
Epsilonproteobacteria, of which Campylobacter is a member, in the infected children
was statistically significant (p < 0.001; FDR < 0.0268) (Fig. 6).
When using LEfSe to analyze all four cohorts, the class Epsilonproteobacteria
was the only one with significant differences (p-value= 0.0011647; FDR = 0.013976;
LDA = 2.98). At the order level, Campylobacterales was the only significantly different
taxon by FDR (p-value= 0.0011647; FDR = 0.01747; LDA = 2.98). Pasteurellales did
have a significant p-value of 0.0202, but the FDR was insignificant at 0.15162. The last
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taxonomic level with a significant LEfSe difference was Family. Campylobacteraceae
was the only significantly different taxon (p-value= 0.0011647; FDR = 0.037269; LDA =
2.98).
While not statistically significant, direct quantitative comparison of taxonomic
abundances from the infected and uninfected cohorts revealed that, at the phylum level,
Firmicutes were similar between both cohorts, while Bacteroidetes had a higher relative
abundance in Campylobacter infected children (19% infected; 13% uninfected). In
contrast, Proteobacteria comprised 32% of the overall relative abundance in uninfected
children and 24% in infected children. At the family level of Proteobacteria, the
percentage of Enterobacteriaceae comprised 98% of the total Proteobacteria
abundance in the uninfected samples yet only 70% in the infected, likely due to
Campylobacteraceae abundance being 2% in uninfected children, but 21% in the
infected cohort (Fig. 7).
When analyzing all four cohorts, more differences noticeable differences among
the cohorts are observed (Fig. 8). Interestingly, the percentage of the phylum
Proteobacteria abundance is 46.7% in CUS compared to the average percentage of
24.5 of the three other cohorts. CUS also has the lowest percentage of Firmicutes (Fig.
8). Although, CUS was culture and qPCR negative for Campylobacter, the percent
abundance at the family level for Campylobacteraceae is higher in this cohort (1.73%)
than in the qPCR positive CIA (0.11%). When looking specifically at the Proteobacteria
phylum, Enterobacteriaceae (E. coli’s family) was lowest in CIS (14.2%) and highest in
CUS (44.9%) (Fig. 9).
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Metabolomic Analysis
Since microbiome analysis by 16S rRNA gene characterization lacks the ability to
give detailed information about the functional microbial activity, metabolomic analysis
can give us a glimpse of the intermediate phenotype mediating host–microbiome
interactions [115]. Using metabolomic analysis of the fecal samples by ultra-highperformance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS), we
observed 533 metabolites (peaks) of which 62 were assigned as specific metabolites in
the database. Differences in metabolite abundance were detected and visualized using
a combination of partial least squares - discriminant analysis (PLS-DA), Random Forest
analysis, and univariate statistics.
PLS-DA demonstrated clustering of most samples to the center with some
separation due to a few samples. This visualization is provided for Campylobacter
infected vs. uninfected in Fig. 10A, and for the separation among all four cohorts in Fig.
11. More specific comparisons of metabolite abundance identified several that were
significantly affected and drove much of the separation observed in the PLS-DA plot of
figure 10A, including three metabolites that were shown to be significantly higher in
uninfected children: ascorbate, cholate, and phenylpyruvate and three in the infected
cohort: hydroxyisocaproic acid, malate, and 2-hydroxy-2-methylsuccinate. It is
interesting that when the cohorts are divided by presence of diarrhea, some trends are
visible. Whereas some of the major metabolites still associate specifically with
Campylobacter infection status, such as cholate and malate, some of the metabolites
seem to possibly associate with the presence of diarrhea such as hydroxyisocaproic
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acid (Fig. 11). The sPLS-DA shows a more significant division between CIS, CUS, CUA
(Fig. 12).
Using an ensemble learning method for classification trees (Random Forest
analysis), we found that folate, riboflavin, lysine, and glutathione disulfide were all lower
in infected children, whereas glucose-1-phosphate, glucose-6-phosphate, orotate,
creatinine, succinate, tryptophan, and others were increased (Fig. 10B). Fig. 13 shows
similar results from the random forest analysis of the four cohorts.
When cross referencing the top 15 metabolites responsible for the separation in
the infected vs. uninfected PLS-DA plot with the top 15 identified by the infected vs.
uninfected Random Forest analysis, we found that 4 metabolites were identified by
both. These metabolites were succinate, tryptophan, leucine, and malate. Once these
metabolites were cross referenced with the results of the four cohort analysis, we found
that tyrosine and malate were the only metabolites present in the top 15 of every single
analysis.

Fecal Micronutrient Comparisons
In addition to examining for changes to metabolites during pediatric Campylobacter
infection, we also quantified using inductively-coupled plasma mass spectrometry (ICPMS) the essential micronutrients cobalt, chromium, copper, iron, manganese,
molybdenum, selenium, and zinc. ICP-MS is capable of detecting metals and several
non-metals at concentrations as low as one part per quadrillion on non-interfered lowbackground isotopes by ionizing the sample with inductively coupled plasma and then
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using a mass spectrometer to separate and quantify those ions [37]. From these fecal
micronutrient profiles, we observed significant decreases for the infected cohort in all,
but chromium (Fig. 14). Statistical analysis of Co, Cr, Cu, Fe, Mn, Mo, Se, and Zn levels
gave p-values = 0.0258, 0.2711, 0.0003, 0.0050, 0.0131, 0.0367, 0.0017, and 0.0009
respectively.
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CHAPTER FIVE – DISCUSSION
Campylobacter jejuni is responsible for 96 million annual cases of bacterialderived gastroenteritis worldwide [2], exceeding the number of cases produced by other
well-known enteric pathogens including strains of pathogenic E. coli and Salmonella [2].
To date, the impacts and mechanisms of Campylobacter infection in human hosts
remain mostly unknown though it appears to affect the developed and developing
worlds in unique ways. One such area is the impact of Campylobacter infection on
pediatric subjects in the developing world, which includes the development of EED,
growth faltering, and cognitive impairment.
It was these negative effects on pediatric populations in the developing world that
initially led us to examine changes to the microbiota, metabolome, and micronutrient
abundances of Colombian children infected with Campylobacter, though it is important
to note that these cohorts were not evaluated for the above conditions (e.g. EED). It is
important to note that in our study, the isolation and testing of Campylobacter was
specifically geared towards C. jejuni and C. coli, which could potentially explain why
Campylobacter 16S rRNA genes were identified in CUS. These could have been non-C.
jejuni/C. coli species that weren’t identified due to targeting C. jejuni/C. coli with our
methods.
Additionally, we sought to determine which sociodemographic variables and
disease manifestations are most often associated with infection. Surprisingly, bird
exposure was more closely associated with the uninfected cohort while children
exposed to domestic cats, while not statistically significant, were approximately five
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times more likely to be in the infected cohort. While cats are seldomly considered a
reservoir of Campylobacter, several studies have reported that a small percentage of
cats are asymptomatically infected with Campylobacter [116-118].
Children with Campylobacter infection were more likely to experience increased
diarrheal episodes in a 24-hour period and more days with diarrhea, which are typical
manifestations of acute Campylobacter infection [119]. Clinical microbial testing found
that Campylobacter-infected children were more likely to be colonized by commensal E.
coli than uninfected children leading us to further examine the impacts of
Campylobacter infection on the gastrointestinal microbiota. These impacts were an
important consideration since: i) the mucosal immune system and intestinal microbiota
are interrelated and develop during the first years of life, ii) diet and enteric infections
shape these systems, and iii) the gastrointestinal immune status and microbiota broadly
impact gut health and nutrient absorption [94, 120-122].
The healthy human gut microbiota is dominated by anaerobes with an
abundance of 2-3 orders of magnitude higher than facultative anaerobes [123].
Dysbiosis occurs when the population of facultative anaerobic bacteria expands due to
a reduction in epithelial hypoxia, which is induced by colonic inflammation – a hallmark
of EED [51]. In an inflammatory environment, terminally differentiated surface
colonocyte metabolism shifts from mitochondrial -oxidation of fatty acids toward
anaerobic glycolysis [61], which results in high glucose consumption, low oxygen, and
increased release of lactate [61]. This shift in colonocyte metabolism ultimately leads to
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elevated amounts of oxygen diffusing to the mucosal surface, which favors the
expansion of facultative anaerobic bacteria [61].
This facultative anaerobic bloom, which is dominated by members of the
Enterobacteriaceae, results in an inflammatory response that alters the nutritional
environment of the gut through the generation of reactive oxygen species (ROS) and
reactive nitrogen species (RNS) [124]. While ROS and RNS have antimicrobial activity,
they are also quickly converted to non-toxic compounds such as nitrate, the most potent
electron acceptor under anaerobic conditions [125]. Since the ability to utilize nitrate
respiration is highly conserved among the Enterobacteriaceae, this nitrate conversion
further supports the expansion of the commensal Enterobacteriaceae present [124].
Another nutrient source provided by host inflammation is migration of neutrophils to the
intestinal lumen, which can produce ROS and convert endogenous sulfur compounds
into electron acceptors such as conversion of thiosulfate into tetrathionate [125]. These
environmental modifications would benefit Campylobacter since its able to use both
nitrate and tetrathionate for respiration [126].
The impact of Campylobacter infection on the pediatric microbiota is
understudied, particularly as it relates to EED development. A recent longitudinal study
of the gut microbiota in young children from southern India [127] found these children
were enriched for Campylobacterales, though the impact of Campylobacter colonization
on microbial community composition was not investigated. In our study, which
examined the relationship of Campylobacter infection and the microbiota, we found that
total relative abundance of Proteobacteria was higher in in uninfected children (32%),
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yet less relatively abundant in the infected subjects (24%). When examining for changes
at the Proteobacteria family level, we observed a shift in the relative abundance of
Enterobacteriaceae from 98% in the uninfected cohort to comprising only 70% in the
infected. We observed a change in Campylobacteraceae abundance of 2% in the
uninfected cohort and 21% in the infected cohort within the phylum, it is possible that
Enterobacteriaceae were displaced by Campylobacter or by Pasteurellaceae, which
was in infected children. These results were interesting in that we did not observe a
change in obligate anaerobes like Bacteroidetes or Firmicutes despite relatively high
numbers of facultative anaerobes in both cohorts. This indicates that the uninfected
children are already abundant for Enterobacteriaceae and that these organisms have
already limited the dominance of anaerobic members of the community.
It is likely that when Campylobacter infection occurs in these children, since the
anaerobic members have already been limited, no further decrease occurs. Since
Campylobacters are predominantly microaerophilic, with an oxygen preference of 312%, the loss of epithelial hypoxia in children enriched for Enterobacteriaceae may
ultimately benefit Campylobacter growth and allow for the persistent colonization that
can occur in children from these communities [51, 126]. This concept is highlight in Fig.
1 with (a) showing a “healthy” epithelial lining [51] and (b) showing what may possibly
be going on to allow Campylobacter asymptomatic colonization.
Analysis of the metabolomes from Campylobacter-uninfected and
Campylobacter-infected children identified several metabolites that were significantly
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different between the two groups. In uninfected children, three metabolites were found
to be higher, including ascorbate, cholate, and phenylpyruvate.
Ascorbate (vitamin C) is of interest as children in the developing world are prone
to low ascorbate and may develop scurvy [128]. Ascorbate boosts intestinal absorption
of non-heme iron and is an important antioxidant that reacts with hydrochlorous acid, a
product of an anti-microbial agent produced by neutrophils via myeloperoxidase (MPO)
[129]. MPO is a commonly used biomarker for inflammation [130] and oxidizes
ascorbate directly leading to depleted ascorbate levels [129]. Although we were unable
to quantify MPO levels due to the limited quantity of sample available, the presence of
fever, diarrhea, and the number of diarrheal episodes in the infected cohort suggests
MPO levels may have been elevated. A plausible explanation for higher ascorbate
levels in the uninfected cohort is that there is less MPO to oxidize the ascorbate in the
intestine allowing for more absorption and excretion.
Cholate was not only higher in the fecal samples of uninfected children relative to
those of infected children, but these results were mirrored in the analysis of the four
cohorts. Cholate is a bile acid that is often converted to the secondary bile acid,
deoxycholate, through microbial dehydroxylation in the colon [131]. Deoxycholate
stimulates the immune system, leading to increased reactive oxygen species (ROS)
generation and negatively impacting the health of intestinal tissue [131].
Phenylpyruvate, higher in the uninfected cohort, is generated from phenylalanine by
oxidative deamination, leading to the replacement of alanine with pyruvate [132].
Conversely, we observed higher levels of phenylalanine in the fecal samples of infected
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children relative to the uninfected, but the four-cohort analysis revealed higher relative
concentrations in symptomatic subjects than Campylobacter-infected subjects. This
suggests reduced catabolism or absorption of the amino acid in the gut of symptomatic
subjects. Phenylalanine is converted to the essential amino acid, tyrosine, by the
enzyme phenylalanine hydroxylase (PAH) [133]. Tyrosine was one of the two
metabolites to be identified in all analyses, and had higher relative concentrations in
symptomatic subjects. Significantly, when a systemic decrease in phenylalanine occurs,
it may lead to decreased systemic levels of tyrosine, as observed in patients with
phenylketonuria (PKU) [133]. This could lead to decreased cognitive function and
physical development, which result from low levels of tyrosine [133]. Since we do not
have dietary records for each subject, we cannot eliminate the possibility that these
differences were caused by variations in diet. The changes in relative concentrations of
essential nutrients detected in the uninfected cohort’s feces are likely explained by an
increase of excretion indicating: 1) poor absorption leading to lower systemic levels, 2)
sufficient systemic levels leading to lack of absorption, or 3) differences in the
microbiota that metabolize these nutrients [125, 134-137].
Additionally, in the symptomatic subjects, we observed higher relative
concentrations in hydroxyisocaproic acid, which is an end-product of leucine
metabolism; malate, which is an intermediate of central metabolism, and
methylsuccinate, which is a methyl-branched fatty acid [138]. We employed a Random
Forest analysis to identify additional molecules that are significantly different between
the groups. From this analysis, we also identified that glucose-1-phosphate, glucose-6-
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phosphate, orotate, creatinine, succinate, and tryptophan were higher in infected
children. Glucose-1-phosphate and glucose-6-phosphate are both intermediates of
many metabolic pathways such as glycolysis, gluconeogenesis, glycogenolysis, and the
pentose phosphate pathway. Orotate is involved in pyrimidine biosynthesis, with
orotidine-5’-monophosphate serving as the final intermediate before uridine
monophosphate synthesis [139]. Creatinine is a byproduct of muscle metabolism and
serum creatinine is often excreted from the body through the urine [140]. Succinate is a
key intermediate in the aerobic TCA cycle, providing electrons to the electron transport
chain for energy production [40]. These changes in relative concentrations suggest that
there was either a large surplus of these metabolites, changes in the host colonocyte
metabolism, or a shift in the microbiota that would reduce the uptake/consumption of
these exceptionally beneficial energy sources.
Tryptophan (Trp) is known for being the least abundant and most conserved
among the 20-common canonical amino acids [141]. Humans primarily rely on dietary
Trp intake, but also on Trp derived from the gut microbiota [141]. Interestingly, Trp
metabolism plays a critical role in mediating immune system-intestinal microbiota
interactions through the detection of Trp-derived metabolites like indole. Campylobacter
could be disturbing this important host pathway by either directly driving Trp
accumulation by synthesizing Trp from indole, or indirectly by altering the microbiota
causing a decrease of Trp metabolism. Recently, a study of a novel mouse model of
Campylobacter-induced enteropathy and diarrhea observed an increase of Trp
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concentrations during Campylobacter infection [142], which was supported by our
observation that Trp was higher in the infected cohort relative to the uninfected.
Micronutrient analyses were performed using ICP-MS for essential metals on all
fecal samples. This technique allowed for the simultaneous detection of cobalt,
chromium, copper, iron, manganese, molybdenum, selenium, and zinc with high
sensitivity [106]. We found that all essential metals except chromium were significantly
reduced by Campylobacter infection. While micronutrient depletion by diarrhea is likely,
the presence of diarrhea was insignificant between cohorts (p-value > 0.057). However,
the number of events and the duration of diarrhea did significantly associate with
infection status (p-value < 0.03). This potentially indicates that having more persistent
diarrhea, which would likely occur during the development of EED, may lead to
micronutrient deficiencies that would impact host development.
We were particularly interested in the reductions in iron and zinc concentrations
because they are associated with immune suppression and decreased development,
two manifestations of EED that were found to correlate with pediatric Campylobacter
infection [143]. On average, adults require a daily intake of iron sufficient to replace that
lost through the GI tract [137]. Children, due to their constant growth and increase in
muscle mass, require the intake of significantly more iron to meet demands [137, 144].
Not only did we observe significantly lower concentrations in iron and zinc, but copper
as well. The lower concentration in copper is supportive of a concomitant diminishment
in iron as anemia may be associated with a deficiency in metals [145]. These results
suggest micronutrient levels have a significant role in Campylobacter infections.
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CHAPTER SIX – RECOMMENDATIONS AND FUTURE WORK
Campylobacter is estimated by the CDC to be the cause of approximately 9% of
all foodborne illnesses in the United States, and 15% of all campylobacteriosis cases
leading to hospitalization [146]. While multiple antibiotic resistant C. jejuni is considered
a “Serious Threat” to public health in the United States [14], Campylobacter is also
implicated in growth faltering among children <2 years of age in low to middle-income
countries [100]. With the mounting evidence regarding the burden of Campylobacterattributed diarrhea as well as growth-faltering in these populations, it is imperative for
research to be conducted to understand Campylobacter’s mechanisms of pathogenesis
and the both the short- and long-term impacts it has on the human host.
This study demonstrated that Campylobacter infection correlated with significant
alterations to the gastrointestinal environment in pediatric populations. In the future, It
would be interesting to analyze the 16S Campylobacter sequences from this study to
identify which species are included in each cohort. This may give insights on species
that may be more associated with asymptomatic colonization or which species were not
identified by our qPCR primers. It would be beneficial to use the weaning-age ferret
model of Campylobacteriosis to replicate the results from this study, and possibly give
more mechanistic data on Campylobacters pathogenesis. In order to more accurately
represent these middle-income populations, a humane induction of malnutrition would
be the best option by decreasing the animals’ food intake by 15%.
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In the future, it would also be interesting to conduct a similar, but longitudinal
study to determine whether any of these children become persistently colonized and
what the impact of that colonization is on the gastrointestinal environment.
Using knowledge gained from the MAL-ED and other similar studies, a
longitudinal study designed specifically for Campylobacter would gain critical knowledge
for the field. Campylobacter is strongly associated with negative outcomes during
colonization of the second year of life [100], so enrolling subjects prior to 6 months of
age and following them until 24 months would be a necessary minimum requirement. To
be collected at the time of enrollment, every month until 1 year, every 3 months until 24
months: 1) a complete clinical and epidemiological questionnaire to be given to the
parents/guardians of the subject, 2) fecal samples from the subject and all members
and animals of the household, and 3) blood and urine sample from subject. If the
subject has a diarrheal episode in between visits, a fresh diarrheal sample, height and
weight measurements would be immediately needed.
The fecal samples would be utilized to characterize the microbial populations by
16S rRNA gene analysis at each time point and diarrheal episode, which would allow
the observation of changes/shifts in the microbiome throughout time or course of
infection. These samples would also be analyzed for biomarkers of intestinal
inflammation and injury, such as methylene blue, fecal occult test, and
myeloperoxidase. These biomarkers would allow insight on the inflammatory status of
the subjects’ gastrointestinal tract [130, 147]. The urine and blood samples would allow
us to determine the systemic micronutrient levels more accurately. This is crucial for
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determining the nutritional status of the subject and how that status may associate with
colonization or infection.
Due to the high genomic plasticity of Campylobacter species, it would be
interesting to utilize whole genome sequencing of Campylobacters isolated from the
feces to see identify potential virulence factors in the genome that may be associated
with a specific disease outcome. This study design would be incredibly useful for
determining what characteristics (host or microbial) that lead to asymptomatic
Campylobacter infections. It would also be informative to perform metagenomics on the
entire fecal population, which could potentially link functional pathways to identified
metabolites from the UHPLC-MS/MS analysis of the samples.
Such a longitudinal study would allow for the identification of children that exhibit
decreased development and whether that outcome is potentially due to alteration in the
gastrointestinal environment. These insights would contribute to EED prevention and/or
treatment leading to enormously positive impacts on pediatric health, but also a
substantially positive economic impact on the developing world.
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Appendix 1
Table 1. Inclusion and exclusion criteria for cohorts

Inclusion

Children less than 60 months of age
Child who resides within the metropolitan area of Bucaramanga, Colombia
Presence or absence of acute, moderate-to-severe *diarrhea and/or vomiting within the
past 10 days.
Diarrhea is moderate to severe and must

(i) Sunken
eyes,
parent/caretaker

confirmed

by

meet at least one of the following criteria:
(ii) Loss of skin turgor by skin pinch (≤2 s slow
or >2 very slow)
(iii) Intravenous rehydration
administered

prescribed

or

(iv) Dysentery (1 or more bloody stools)
(v) Evaluated in the emergency department or
admitted to the hospital for diarrhea
Exclusion

Children older than 60 months of age
Children who reside outside of the metropolitan area of Bucaramanga, Colombia

Presence of chronic diarrhea (>10 days) or other comorbid conditions such as Crohn’s
disease or ulcerative colitis
(*) The World Health Organization defines diarrhea as 3 or more episodes of loose or liquid stools within
24 hours
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Table 2. Sociodemographic of subjects
Variable

Infected (%)

Uninfected (%)

p-value1

Male

8 (40)

6 (30)

0.204

Female

12 (60)

14 (70)

Mestizo

14 (70)

14 (70)

White

6 (30)

6 (30)

0 to 12

5 (25)

9 (45)

0.320

12 to 24

11 (55)

4 (20)

0.048

24 to 60

4 (20)

7 (55)

0.480

Gender

Race
1

Age Group (months)

1Two-sided

p-values were generated using Fisher’s Exact Test.
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Table 3. Sociodemographic of subjects
Variable

1 (%)

2 (%)

3 (%)

4 (%)

Gender

0.47

Male

5 (35)

3 (50)

2 (25)

4 (33%)

Female

9 (65)

3 (50)

6 (75)

8 (67%)

Race

0.87

Mestizo

9 (64)

5 (83)

2 (25)

12 (100)

White

5 (36)

1 (17)

6 (75)

0 (0)

Age Group (months)

0.71

0 to 12

3 (21)

2 (33.3)

3 (37.5)

6 (50)

12 to 24

9 (64)

2 (33.3)

2 (25)

2 (16)

24 to 60

2 (14)

2 (33.3)

3 (37.5)

4 (34)

Total Subjects

14

6

8

12

1Two-sided

p-value1

p-values were generated using Kruskal-Wallis Test.
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Table 4. Clinical Symptoms of cohorts
Fever

Infected

14

(%)

(70)

Uninfected

Vomiting

Diarrhea

Antidiarrheal in

Blood

Mucus

Abdominal

last 14 days

in stool

in stool

pain

10 (50)

14 (70)

9 (45)

4 (20)

15 (75)

6 (30)

8 (40)

7 (35)

8 (40)

4 (20)

4 (20)

10 (50)

5 (25)

0.056

0.337

0.056

0.091

1

0.102

0.723

(%)

p-value1

1Two-sided

p-values were generated using Chi Squared Test.
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Table 5. Animal and illness exposure
Any

Bird

Cat

Dog

Chicken

Animal

International

Exposure

Exposure

Attends

Travel

to

to

Daycare

diarrhea

diarrhea

(outside

(inside of

of home)

home)

Exposure

Infected

10 (50)

0 (0)

7

8

(35)

(40)

7

2

8

(35)

(10)

(40)

0.003

0.058

1

(%)

Uninfected

8 (40)

(%)

p-value1

1Two-sided

0.525

3 (15)

2 (10)

1 (5)

1 (5)

4 (20)

2 (20)

2 (10)

0 (0)

1 (5)

5 (25)

0.632

0.465

0.311

1

0.705

p-values were generated using Chi Squared Test.
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Table 6. Proportion of infected subjects by either single or multiple pathogens
(co-infections)
Pathogens

Total (%)

Infected (%)

Uninfected (%)

p-value1

Giardia lamblia

2 (5)

2 (10)

0 (0)

0.4872

Blastocytis

2 (5)

0 (0)

2 (10)

0.4872

Campylobacter

20 (50)

20 (100)

0 (0)

<0.0001

Commensal E. coli

29 (72.5)

16 (80)

11 (55)

0.1760

Pathogenic E. coli

4 (10)

2 (10)

2 (10)

1

Norovirus

3 (7.5)

3 (15)

0 (0)

0.230

Sapovirus

1 (2.5)

1 (5)

0 (0)

1

Co-infections

6 (15)

3 (15)

1 (5)

0.6050

Negative for any pathogen

17 (42.5)

0 (0)

17 (85)

0.0001

1Two-sided

p-values were generated using Fisher’s Exact Test
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Table 7. Proportion of infected subjects by either single or multiple pathogens
(co-infections)
Pathogens

Total (%)

1 (%)

2 (%)

3 (%)

4 (%)

Giardia lamblia

2 (5)

1

1

0

0

Blastocytis

2 (5)

0

0

1

1

Campylobacter

20 (50)

14

6

0

0

Commensal E. coli

29 (72.5)

11

5

5

6

Pathogenic E. coli

4 (10)

2

0

0

2

Norovirus

3 (7.5)

2

1

0

0

Sapovirus

1 (2.5)

1

0

0

0

Co-infections

7 (17.5)

5

1

0

1

Negative for any pathogen

17 (42.5)

0 (0)

0 (0)

7 (87.5)

10 (83)
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Figure 1. Epithelial metabolism and the colonic microbiota.
(a) When the gut microbiota is in homeostasis, the obligate anaerobic microbes will
metabolize fiber from the diet to produce fermentation products such as butyrate that
will help maintain the -oxidation metabolic state of the colonocyte. This metabolic state
is characterized by high oxygen consumption which allows for the maintenance of the
epithelial hypoxia (<1% oxygen) to limit the amount of oxygen that diffuses into the
lumen. (b) A dysbiosis of the microbiota would reduce the production of fermentation
products such as butyrate, which leads to the colonocyte to switch from -oxidation to
anaerobic glycolysis. This metabolic shift would allow for oxygen, lactate, and nitrate
concentrations in the lumen to significantly increase.
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Figure 2. Rarefaction Curve of 16S rRNA Amplicons
(a) Rarefaction curve of samples before normalization. (b) Rarefaction curve of
samples after normalization by rarefying data.
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Figure 3. Bacterial Diversity Measures Between Infected and Uninfected Cohorts
(A) Alpha Diversity was calculated by Shannon index using richness and evenness to
describe the actual diversity of the communities, which is represented as a box plot at
the genus level. Each boxplot represents the diversity distribution present within each
group (p-value = 0.18744). (B) Beta Diversity was calculated using the phylogeneticbased weighted unifrac distances and visualized using Principle Coordinate Analysis
(PCoA) plots. The X-axis represents the percent of the variation between the samples
with the X-axis representing the highest dimension of variation and the Y-axis
representing the second highest dimension of variation (p-value = 0.074).
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Alpha-diversity Index: Shannon
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Figure 4. Alpha Diversity of the Four Cohorts
Alpha Diversity was calculated by Shannon index using richness and evenness to
describe the actual diversity of the communities, which is represented as a box plot at
the OTU level. Each boxplot represents the diversity distribution present within each
group (p-value = 0.36257). n’s of cohorts CIS, CIA, CUS, CUA are 14, 6, 8, and 12,
respectively.
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Figure 5. Beta Diversity of the Four Cohorts
Beta Diversity was calculated using the Jensen-Shannon Divergence Index and
visualized using Principle Coordinate Analysis (PCoA) plots. The X-axis represents the
percent of the variation between the samples with the X-axis representing the highest
dimension of variation and the Y-axis representing the second highest dimension of
variation (p-value = 0.121). n’s of cohorts CIS, CIA, CUS, CUA are 13, 6, 8, and 12,
respectively.
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Figure 6. Univariate Analysis Between Campylobacter-Infected and Uninfected
Microbiomes
The univariate analysis of Epsilonproteobacteria using Mann-Whitney/Kruskal-Wallis ttest resulted in a p-value < 0.001; FDR < 0.0268 (n=19 infected; n=20 uninfected).
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Figure 7. Microbiome Differences Between Campylobacter-infected and
uninfected Samples
The combined infected (A) and uninfected (B) relative abundances found in the
microbiome at the phylum level, along with the combined infected (C) and uninfected
(D) relative abundances found in the microbiome at the family level are shown as a pie
chart to demonstrate changes that occurred (n=19 infected; n=20 uninfected).
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Figure 8. Phylum Level Microbiome Differences between the Four Cohorts
Relative abundances found in the microbiome at the phylum level between the four
cohorts. n’s of cohorts CIS, CIA, CUS, CUA are 13, 6, 8, and 12, respectively.
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Figure 9. Proteobacteria's Family Level Microbiome Differences between the Four
Cohorts
Relative abundances found in the microbiome at the Proteobacteria’s family level
between the four cohorts. n’s of cohorts CIS, CIA, CUS, CUA are 13, 6, 8, and 12,
respectively.
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Figure 10. Metabolomic differences between infected and uninfected samples
(A) The differences between the metabolomes of the Campylobacter infected and
uninfected samples were determined by using the Least Partial Squares – Discriminant
Analysis (PLS-DA). The visualization of these differences is plotted 2-dimensionally with
each point representing the metabolomic profile of a single sample (N=40, 20 per
group). (B) The top 15 metabolites determined by Random Forest analysis to have the
highest discriminatory power between the two groups with red fields representing high
abundance and green fields representing low abundance for each metabolite per
infection status.
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Figure 11. PLS-DA Plot of the Four Cohorts
The differences between the metabolomes of the four cohorts’ fecal samples were
determined by using the Least Partial Squares – Discriminant Analysis (PLS-DA). The
visualization of these differences is plotted 2-dimensionally with each point representing
the metabolomic profile of a single sample. n’s of cohorts CIS, CIA, CUS, CUA are 14,
6, 8, and 12, respectively.
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Figure 12. PLS-DA VIP Scores
The differences between the metabolomes of the four cohorts’ fecal samples were
determined by using the Least Partial Squares – Discriminant Analysis (PLS-DA). (a)
Metabolite VIP scores from Component 1. (b) Metabolite VIP scores from component 2.
n’s of cohorts CIS, CIA, CUS, CUA are 14, 6, 8, and 12, respectively.
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Figure 13. sPLS-DA Plot of Four Cohorts
The differences between the metabolomes of the four cohorts’ fecal samples were
determined by using the Sparse Least Partial Squares – Discriminant Analysis (sPLSDA).
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Figure 14. Micronutrient differences between infected and uninfected samples
Different colored data points were used to represent the different isotopes measured by
the ICP-MS (orange represents 59Co, 52Cr, 63Cu, 56Fe, 55Mn, 95Mo, 78Se, and 66Zn; grey
represents 53Cr, 65Cu, 57Fe, 98Mo, 82Se, and 64Zn). The asterisks represent significance
calculated by unpaired t-tests (*p < 0.05, **p < 0.005, **p < 0.001; n=17 infected, n=19
uninfected).
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Appendix 2

Appendix 2- 1. Percent Abundances at Phylum Level

Appendix 2- 2. Percent Abundances at Class Level
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Appendix 2- 3. Percent Abundance at Order Level

90

Appendix 2- 4. Percent Abundance at Family Level
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Appendix 2- 5.LEfSe Output at Phylum Level

Appendix 2- 6. LEfSe Output at Class Level
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Appendix 2- 7. LEfSe Output at Order Level

93

Appendix 2- 8. LEfSe Output at Family Level
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Appendix 2- 9. LEfSe Output at Genus Level
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Appendix 2- 10. Actual Abundances
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Appendix 2- 11. Unfiltered Goods Coverage
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Appendix 2- 12. Filtered Goods Coverage
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Appendix 2- 13. Metabolome PCA of Four Cohorts
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a

b

Appendix 2- 14. sPLS-DA Loadings
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Appendix 2- 15. Microbiome Univariate Analysis of Four Cohorts
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Appendix 2- 16. PLS-DA Loadings
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Appendix 2- 17. Actual Relative Abundance of Microbiome
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Appendix 2- 18. Relative Abundance of Microbiome Based on Percentage
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Appendix 2- 19. Actual Relative Abundance of Individual Subjects Microbiomes
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Appendix 2- 20. Relative Abundance of Individual Subjects' Microbiome Based on
Percentage
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Appendix 2- 21. PCoA Plot of Beta-Diversity of Four Cohorts
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Appendix 2- 22. PCoA Plot of Beta-Diversity of Four Cohorts
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Appendix 2- 23. Random Forest of Microbiome Classification Plot
The number of trees to grow was set to 1000, with 7 predictors, and randomness setting
turned on.
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Appendix 2- 24. Random Forest Results at Class Level
The number of trees to grow was set to 1000, with 7 predictors, and randomness setting
turned on.
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Appendix 2- 25. Random Forest Results at Order Level
The number of trees to grow was set to 1000, with 7 predictors, and randomness setting
turned on.

112

Appendix 2- 26. Random Forest Results at Family Level
The number of trees to grow was set to 1000, with 7 predictors, and randomness setting
turned on.
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Appendix 2- 27. Random Forest Results at Genus Level
The number of trees to grow was set to 1000, with 7 predictors, and randomness setting
turned on.
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Appendix 2- 28. Random Forest Classification Plot
The number of trees to grow was set to 5000, with 7 predictors, and randomness setting
turned on.
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Appendix 2- 29. Random Forest Results at Family Level
The number of trees to grow was set to 5000, with 7 predictors, and randomness setting
turned on.
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Appendix 2- 30. Dendrogram based on Metabolomic Analysis
This dendrogram was created using Euclidean ward model.

117

Appendix 2- 31. Metabolome Heat Map 1
This heat map was created based on the distance measure of Euclidean ward and
statistical method of T-Test/ANOVA.
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Appendix 2- 32. Metabolome Heatmap 2
This heat map was created based on the distance measure of Euclidean ward and
statistical method of T-Test/ANOVA. Same as Heatmap 1, but in color.
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Appendix 2- 33. Metabolome Heatmap 3
This heat map was created based on the distance measure of Euclidean ward and VIP
results.
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Appendix 2- 34. Metabolome Heatmap 4
This heat map was created based on the distance measure of Euclidean average and
statistical method of T-Test/ANOVA.
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Appendix 2- 35. Metabolome Heatmap 5
This heat map was created based on the distance measure of Pearson ward and
statistical method of T-Test/ANOVA.
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Appendix 2- 36. Metabolome Heatmap 6
This heat map was created based on the distance measure of Minkowsi ward and
statistical method of T-Test/ANOVA.
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Appendix 2- 37. Metabolome Random Forest Classification Plot
The number of trees was set to 5000, with 7 predictors, and randomness turned on.
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Appendix 2- 38. Metabolome Random Forest Results
The number of trees was set to 5000, with 7 predictors, and randomness turned on. The
OOB error is equal to .625.
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Appendix 2- 39. Metabolome Random Forest Outlier Detection Results
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The NPAR1WAY Procedure

Distribution of Wilcoxon Scores for daysofdiarrhea
40

Pr > Z 0.0151
Pr > |Z| 0.0302

Score

30

20

Pr > Z 0.0151
Pr > |Z| 0.0302

10
Yes

No

Case

Appendix 2- 40. Epidemiological Data SAS Output
Raw SAS statistical data outputs for epidemiological data for Campylobacter infected in
comparison to Campylobacter uninfected. (pages 1- 66)
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Appendix 2- 41. Z-Score Analysis of Subjects
Raw SAS statistical data outputs determining subject Z-scores (a value's relationship to
the mean of a group of values, measured in terms of standard deviations from the
mean). This specifically evaluated the subjects Z-scores in relation to underweight,
wasting, and stunting of growth. (n=40, 20 per group)
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Data Input
Original
Original
Original
Original
Original
Original
Original
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered

Taxonomic Level
Plylum
Class
Order
Family
Genus
Species
OTU
Plylum
Class
Order
Family
Genus
Species
OTU

Diversity Measue
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1
Chao1

Statistical Method
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA

Data Input
Original
Original
Original
Original
Original
Original
Original
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered

Taxonomic Level
Plylum
Class
Order
Family
Genus
Species
OTU
Plylum
Class
Order
Family
Genus
Species
OTU

Diversity Measue
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon

Statistical Method
p-value
KW Value
Mann-Whitney / Krustal-Wallis
0.22203
Mann-Whitney / Krustal-Wallis
0.47628
Mann-Whitney / Krustal-Wallis
0.32863
Mann-Whitney / Krustal-Wallis
0.36704
Mann-Whitney / Krustal-Wallis
0.3829
Mann-Whitney / Krustal-Wallis
0.36865
Mann-Whitney / Krustal-Wallis
0.34447
Mann-Whitney / Krustal-Wallis
0.1758
Mann-Whitney / Krustal-Wallis
0.46558
Mann-Whitney / Krustal-Wallis
0.40643
Mann-Whitney / Krustal-Wallis
0.39615
Mann-Whitney / Krustal-Wallis
0.39521
Mann-Whitney / Krustal-Wallis
0.32112
Mann-Whitney / Krustal-Wallis
0.32657

0.4393
2.4945
3.44
3.1639
3.0578
3.1529
3.3229
4.946
2.5542
2.9055
2.9708
2.9769
3.4973
3.4556

Data Input
Original
Original
Original
Original
Original
Original
Original
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered

Taxonomic Level
Plylum
Class
Order
Family
Genus
Species
OTU
Plylum
Class
Order
Family
Genus
Species
OTU

Diversity Measue
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson
Simpson

Statistical Method
p-value
KW Value
Mann-Whitney / Krustal-Wallis
0.27574
Mann-Whitney / Krustal-Wallis
0.3452
Mann-Whitney / Krustal-Wallis
0.26787
Mann-Whitney / Krustal-Wallis
0.26787
Mann-Whitney / Krustal-Wallis
0.29171
Mann-Whitney / Krustal-Wallis
0.30581
Mann-Whitney / Krustal-Wallis
0.24582
Mann-Whitney / Krustal-Wallis
0.18889
Mann-Whitney / Krustal-Wallis
0.44666
Mann-Whitney / Krustal-Wallis
0.33791
Mann-Whitney / Krustal-Wallis
0.41877
Mann-Whitney / Krustal-Wallis
0.48067
Mann-Whitney / Krustal-Wallis
0.34021
Mann-Whitney / Krustal-Wallis
0.22074

3.871
3.3176
3.9413
3.9413
3.7335
3.6177
4.149
4.7767
2.6624
3.3708
2.8388
2.4704
3.3539
4.407

Data Input
Original
Original
Original
Original
Original
Original
Original
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered

Taxonomic Level
Plylum
Class
Order
Family
Genus
Species
OTU
Plylum
Class
Order
Family
Genus
Species
OTU

Diversity Measue
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1
Choa1

Statistical Method
p-value
KW Value
Mann-Whitney / Krustal-Wallis
0.50643
2.3319
Mann-Whitney / Krustal-Wallis
0.93606
0.42008
Mann-Whitney / Krustal-Wallis
0.71238
1.3708
Mann-Whitney / Krustal-Wallis
0.6353
1.7079
Mann-Whitney / Krustal-Wallis 0.659865
1.6033
Mann-Whitney / Krustal-Wallis
0.57933
1.9668
Mann-Whitney / Krustal-Wallis 0.061167
7.3637
Mann-Whitney / Krustal-Wallis
0.17268
4.9879
Mann-Whitney / Krustal-Wallis
0.07206
6.9949
Mann-Whitney / Krustal-Wallis
0.03403
8.6691
Mann-Whitney / Krustal-Wallis
0.6487
1.6472
Mann-Whitney / Krustal-Wallis
0.87162
0.70674
Mann-Whitney / Krustal-Wallis
0.80788
0.9726
Mann-Whitney / Krustal-Wallis
0.72175
1.3312
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p-value
ANOVA (F-value)
0.70401
0.4717
0.99023
0.037205
0.92204
0.16069
0.92218
0.16046
0.63386
0.577736
0.64322
0.56285
0.45222
2.9752
0.22058
1.5454
0.3068
1.2505
0.30409
1.2584
0.66041
0.53656
0.97433
0.072445
0.94355
0.12683
0.91937
0.164776

Data Input
Original
Original
Original
Original
Original
Original
Original
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered

Taxonomic Level
Plylum
Class
Order
Family
Genus
Species
OTU
Plylum
Class
Order
Family
Genus
Species
OTU

Diversity Measue
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon
Shannon

Statistical Method
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA
T-Test/ANOVA

p-value
ANOVA (F-value)
0.27549
1.347
0.22322
1.5348
0.13213
2.0025
0.12016
2.0875
0.21272
1.5778
0.16601
1.7987
0.13442
1.9871
0.20763
1.5994
0.25778
1.4064
0.15757
1.8452
0.13355
1.9929
0.196998
1.6462
0.14517
1.9184
0.1169
2.1122

Data Input
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered
Filtered
Original
Original
Original
Original
Original
Original
Original
Original

Taxonomic Level
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU
OTU

Diversity Measue
Observed
Observed
Ace
Ace
Simpson
Simpson
Fisher
Fisher
Observed
Observed
Ace
Ace
Simpson
Simpson
Fisher
Fisher

Statistical Method
p-value
T-Test/Anova
0.82837
Mann-Whitney / Krustal-Wallis
0.89257
T-Test/Anova
0.86653
Mann-Whitney / Krustal-Wallis
0.79783
T-Test/Anova
0.020358
Mann-Whitney / Krustal-Wallis
0.21192
T-Test/Anova
0.88718
Mann-Whitney / Krustal-Wallis 0.892527
T-Test/Anova
0.1125
Mann-Whitney / Krustal-Wallis
0.23843
T-Test/Anova
0.017768
Mann-Whitney / Krustal-Wallis 0.033387
T-Test/Anova
0.019404
Mann-Whitney / Krustal-Wallis
0.24582
T-Test/Anova
0.18889
Mann-Whitney / Krustal-Wallis
0.2975

Appendix 2- 42. Alpha-Diversity Statistics Table for the Four Cohorts
The low count filter setting was equal to 4 and prevalence in sample was set to 20%,
while the low variance filter was set to remove 10% based on the inter-quantile range.
The data was normalized by rarefying but did not scale or transform data. All statistically
significant p-vales are highlighted in yellow.
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Taxonomic Level
Phylum
Phylum
Phylum
Class
Class
Class
Order
Order
Order
Family
Family
Family
Genus
Genus
Genus
Species
Species
Species
OTU
OTU
OTU

Distance Method
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis
Bray-Curtis

Statistical Method
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP

p-value

Taxonomic Level
Phylum
Phylum
Phylum
Class
Class
Class
Order
Order
Order
Family
Family
Family
Genus
Genus
Genus
Species
Species
Species
OTU
OTU
OTU

Distance Method
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence
Jensen-Shannon Divergence

Statistical Method
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP

p-value

Taxonomic Level
Phylum
Phylum
Phylum
Class
Class
Class
Order
Order
Order
Family
Family
Family
Genus
Genus
Genus
Species
Species
Species
OTU
OTU
OTU

Distance Method
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index
Jaccard Index

Statistical Method
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP
PERMANOVA
ANOSIM
PERMDISP

p-value

0.2
0.269
0.71599
0.2
0.269
0.71599
0.2
0.269
0.71599
0.2
0.269
0.71599
0.2
0.269
0.71599
0.2
0.269
0.71599
0.2
0.269
0.71599

0.227
0.249
0.68747
0.227
0.249
0.68747
0.227
0.249
0.68747
0.227
0.249
0.68747
0.227
0.249
0.68747
0.227
0.249
0.68747
0.227
0.249
0.68747

0.164
0.269
0.56335
0.164
0.269
0.56335
0.164
0.269
0.56335
0.164
0.269
0.56335
0.164
0.269
0.56335
0.164
0.269
0.56335
0.164
0.269
0.56335
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Appendix 2- 43. Beta-Diversity of the Four Cohorts
The low count filter setting was equal to 4 and prevalence in sample was set to 20%,
while the low variance filter was set to remove 10% based on the inter-quantile range.
The data was normalized by rarefying but did not scale or transform data. All statistically
significant p-vales are highlighted in yellow.

Taxonomic Level
OTU
OTU
OTU
OTU

Diversity Measue
Choa1
Choa1
Shannon
Shannon

Taxonomic Level Distance Method
OTU
Bray-Curtis

Statistical Method
p-value
T-Test/ANOVA
Man-Whitney/Krustal-Wallis
T-Test/ANOVA
Man-Whitney/Krustal-Wallis

Statistical Method
PERMANOVA

0.81555
0.8301
0.26829
0.111

p-value
0.219

Appendix 2- 44. Alternative Data Filtering and Normalization Statistics
The low count filter setting was equal to 2 and prevalence in sample was set to 20%,
while the low variance filter was set to remove 5% based on the inter-quantile range.
The data was normalized by rarefying but did not scale or transform data. After Filtration
there was 404 features remaining.
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Taxonomic Level
OTU
OTU
OTU
OTU

Diversity Measue
Choa1
Choa1
Shannon
Shannon

Taxonomic Level Distance Method
OTU
Bray-Curtis

Statistical Method
p-value
T-Test/ANOVA
Man-Whitney/Krustal-Wallis
T-Test/ANOVA
Man-Whitney/Krustal-Wallis

Statistical Method
PERMANOVA

0.81555
0.8301
0.26829
0.111

p-value
0.219

Appendix 2- 45. Alternative Data Filtering and Normalization Statistics
The low count filter setting was equal to 2 and prevalence in sample was set to 20%,
while the low variance filter was set to remove 5% based on the inter-quantile range.
The data was normalized by rarefying with total sum scaling.

Taxonomic Level
OTU
OTU
OTU
OTU

Diversity Measue
Choa1
Choa1
Shannon
Shannon

Taxonomic Level Distance Method
OTU
Bray-Curtis

Statistical Method
p-value
T-Test/ANOVA
Man-Whitney/Krustal-Wallis
T-Test/ANOVA
Man-Whitney/Krustal-Wallis

Statistical Method
PERMANOVA

0.93641
0.9874
0.26695
0.10842

p-value
0.223

Appendix 2- 46. Alternative Data Filtering and Normalization Statistics
The low count filter setting was equal to 2 and prevalence in sample was set to 20%,
while the low variance filter was set to remove 5% based on the inter-quantile range.
The data was not normalized in anyway.
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Taxonomic Level
OTU
OTU
OTU
OTU

Diversity Measue
Choa1
Choa1
Shannon
Shannon

Taxonomic Level Distance Method
OTU
Bray-Curtis

Statistical Method
p-value
T-Test/ANOVA
Man-Whitney/Krustal-Wallis
T-Test/ANOVA
Man-Whitney/Krustal-Wallis

Statistical Method
PERMANOVA

0.81555
0.83301
0.26829
0.111

p-value
0.219

Appendix 2- 47. Alternative Data Filtering and Normalization Statistics
The low count filter setting was equal to 2 and prevalence in sample was set to 20%,
while the low variance filter was set to remove 5% based on the inter-quantile range.
The data was normalized by only total sum scaling.

Taxonomic Level
OTU
OTU
OTU
OTU

Diversity Measue
Choa1
Choa1
Shannon
Shannon

Taxonomic Level Distance Method
OTU
Bray-Curtis

Statistical Method
p-value
T-Test/ANOVA
Man-Whitney/Krustal-Wallis
T-Test/ANOVA
Man-Whitney/Krustal-Wallis

Statistical Method
PERMANOVA

0.93641
0.9874
0.26695
0.10842

p-value
0.223

Appendix 2- 48. Alternative Data Filtering and Normalization Statistics
The low count filter setting was equal to 2 and prevalence in sample was set to 20%,
while the low variance filter was set to remove 5% based on the inter-quantile range.
The data was normalized by rarefying with relative log expression.
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Taxonomic Level
OTU
OTU
OTU
OTU

Diversity Measue
Choa1
Choa1
Shannon
Shannon

Taxonomic Level Distance Method
OTU
Bray-Curtis

Statistical Method
p-value
T-Test/ANOVA
Man-Whitney/Krustal-Wallis
T-Test/ANOVA
Man-Whitney/Krustal-Wallis

Statistical Method
PERMANOVA

0.82533
0.73211
0.34352
0.12077

p-value
0.201

Appendix 2- 49. Alternative Data Filtering and Normalization Statistics
The low count filter setting was equal to 6 and prevalence in sample was set to 25%,
while the low variance filter was set to remove 15% based on the inter-quantile range.
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